Document:

EX-10.1

  Exhibit 10.1

   

   

  One Sansome St. 33rd Floor

  San Francisco, CA 94104 

  hr@wish.com

   

  September 7, 2022
 

  VIA EMAIL

  Jun (Joe) Yan

   

  Dear Joe:

  ContextLogic Inc. (the “Company” or “Wish”) is pleased to offer you employment in our San Francisco office, on the following terms:

  1.Position and Start Date. Your title will be Interim Chief Executive Officer. In this role, you will report to the Company’s Board of Directors and you will be expected to perform such duties and exercise such responsibilities as are assigned from time-to-time. In carrying out these duties and responsibilities, you shall comply with all policies, procedures, rules and regulations, both written and oral, as are provided by the Company from time-to-time, and carry out said duties and responsibilities in a diligent, faithful and honest manner. Your employment start date with the Company will be a date as may be mutually agreed upon by you and the Company which is subsequent to your satisfaction of the employment contingencies set forth herein (“Start Date”).

  2.Compensation.  The Company will pay you a starting base salary of $550,000 per year, payable in accordance with the Company’s standard payroll schedule.  This salary will be subject to adjustment pursuant to the Company’s employee compensation policies and procedures in effect from time to time.  

  3.Relocation Bonus. This offer includes a relocation bonus in the amount of $200,000, which will be paid to you within ten (10) business days of your Start Date, and is intended to cover your relocation to the San Francisco Bay Area and all associated expenses. If you are terminated for cause by the Company before the one-year anniversary of your Start Date, you agree to repay the Company the full net amount of the relocation bonus within 30 days of your separation date. For purposes of the relocation bonus, “cause” shall mean (i) your willful and intentional unauthorized use or disclosure of the Company’s confidential information or trade secrets, which use or disclosure causes material harm to the Company, (ii) your material breach of any agreement with the Company, (iii) your material failure to comply with the Company’s written policies or rules, (iv) your conviction of, or plea of “guilty” or “no contest” to, a felony under the laws of the United States or any State, (v) your gross negligence or willful misconduct which results in material harm to the Company, (vi) your continuing failure to perform assigned duties after receiving written notification from the Company’s Board of Directors (other than as a result of having a disability that prevents you from performing the material duties required of a person holding the position with the Company for a period of at least 120 days) or (vii) your failure to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested such cooperation. In the case of clauses (ii), (iii) and (vii), the Company will not terminate your employment for cause without first giving you written notification of the acts or omissions constituting cause and a reasonable cure period of not less than 10 days following such notice to the extent such events are curable (as determined by the Company).

  4.Employee Benefits.  As a regular employee of the Company, you will be eligible to participate in a number of Company-sponsored benefits, including our group health insurance plan, in accordance with the applicable plan documents and policies. The Company reserves the right to modify or discontinue such benefit plans in its sole discretion. In addition, you will be eligible to participate in the Company’s paid time off policy, as in effect from time to time. A copy of the current paid time off policy will be provided to you upon hire and any subsequent versions will be posted on the Company’s wiki/intranet.  

  

  5.Restricted Stock Units. Subject to the approval of the Company’s Board of Directors or its Compensation Committee, you will be granted an award of Restricted Stock Units (“RSUs”) for that number of shares of the Company’s Common Stock equal to $3,000,000 divided by the average closing price of a share of the Company’s Common Stock as reported on Nasdaq during the full calendar month prior to your Start Date, rounded down to the nearest whole share. The RSUs will vest over time based on your continuous service with the Company, with 50% of the RSUs vesting on the first Company Vesting Date following your completion of 6 months of continuous service; provided, however, that if the Company terminates your employment, you do not remain the Company’s Interim Chief Executive Officer or become the Company’s Chief Executive Officer, in each case prior to your completion of 6 months of employment with the Company, such RSUs will accelerate and vest and settle on the first Company Vesting Date thereafter. The remaining 50% of the RSUs will vest on the Company Vesting Date following your completion of 12 months of continuous service. For the avoidance of doubt, “service” for purposes of the RSUs shall include service as an employee, consultant or director. A “Company Vesting Date” means February 15th, May 15th, August 15th, or November 15th. The Company intends to grant the RSU award as an “inducement grant” (within the meaning of Nasdaq Marketplace Rule 5635(c)(4)) pursuant to the Company’s 2022 New Employee Equity Incentive Plan (the “Plan”), and the RSU award will be subject to the terms and conditions of the Plan as well as the applicable Notice of Restricted Stock Unit Award and Restricted Stock Unit Agreement.

  6.Stock Options. Subject to the approval of the Company’s Board of Directors or its Compensation Committee, you will be granted an option to purchase that number of shares of the Company’s Class A Common Stock equal to $3,000,000 divided by the average closing price of a share of the Company’s Common Stock as reported on Nasdaq during the full calendar month prior to your Start Date, rounded down to the nearest whole share (the “Option”). The exercise price per share of the Option will be equal to the fair market value of the Company’s Class A Common Stock on the date of grant, which is your Start Date. The Option will vest and become exercisable over time based on your continuous service with the Company, with 50% of the Option shares vesting on the 6 month anniversary of your Start Date; provided, however, that if the Company terminates your employment, you do not remain the Company’s Interim Chief Executive Officer or become the Company’s Chief Executive Officer, in each case prior to your completion of 6 months of continuous employment with the Company, such Option shares will accelerate and immediately vest, and remain exercisable in accordance with their terms thereafter. The remaining 50% of the Option shares will vest on the 12 month anniversary of your Start Date, provided that you remain in continuous service through such date. For the avoidance of doubt, “service” for purposes of the Option shall include service as an employee, consultant or director. The Company intends to grant the Option as an “inducement grant” (within the meaning of Nasdaq Marketplace Rule 5635(c)(4)) pursuant to the Plan, and the Option will be subject to the terms and conditions of the Plan as well as the applicable Notice of Stock Option Grant and Stock Option Agreement.

  7.Confidential Information and Invention Assignment Agreement.  Like all Company employees, you will be required, as a condition of your employment with the Company, to sign the Company’s standard Confidential Information and Invention Assignment Agreement, a copy of which is attached hereto as Exhibit A. We also want to make clear that we do not want you to, and we hereby direct you not to, bring with you any confidential or proprietary information of any former employer or other entity or to violate any other obligations you may have to any former employer or other entity. By signing this agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prevent you from performing your duties for the Company.

  8.Conflicts of Interest. During your employment, you agree not to engage in any employment, business, or activity that is in any way competitive with the business or proposed business of the Company, which materially interferes with the performance of your job duties, or creates a conflict of interest (this includes any other full-time employment arrangements); provided, however, that you may continue to provide services and/or continue to engage in the current business activities that you list on Exhibit B hereto during your employment with the Company. During your employment with the Company, you may request (and submit to Wish for approval) an Outside Activity Disclosure Form from hr@wish.com to disclose any other outside employment, business, or activity in which you intend to engage during employment with Wish. Failure to make disclosures is considered a material representation that you are not engaged or associated with any such outside activities at the beginning of employment. You will be responsible for complying with Wish’s Conflict of Interest Policy, including updated disclosures of such outside activities, at all times during employment.

  

  9.Employment Relationship.  Employment with the Company is at-will. This means that you have the right to resign and the Company has the right to terminate your employment at any time, for any or no reason, with or without cause, and with or without notice. Any contrary representations that may have been made to you are superseded by this letter agreement. This, along with the Confidential Information and Invention Assignment Agreement, is the full and complete agreement between you and the Company on this term. Although your job duties, title, responsibilities, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and the Board of Directors of the Company. At the sole discretion of the Company, you agree to serve, without additional compensation, as a director, officer, or member of the board of directors (collectively, “officer positions”) of any of the Company’s subsidiaries, partnerships, joint ventures or other affiliates. If your employment with the Company is terminated for any reason, whether such termination is voluntary or involuntary, you agree to take all necessary actions, as reasonably requested by the Company, to resign from all officer positions.

  10.Tax Matters.

  (a)Withholding.  All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.

  (b)Tax Advice.  You are encouraged to obtain your own tax advice regarding your compensation from the Company.  You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its Board of Directors related to tax liabilities arising from your compensation.

  11.Interpretation, Amendment and Enforcement.  This letter agreement and the accompanying exhibits, including the Confidential Information and Invention Assignment Agreement, along with documents related to your equity grants, constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior between you and the Company. This letter agreement may only be amended by an authorized officer of the Company.  

  12.Arbitration of Disputes.  The Company and I mutually consent to the resolution by arbitration, under the applicable rules of JAMS (which are available at jamsadr.com, or from the Company upon my request), of all claims (common law or statutory) that the Company might have against me, or that I may have against the Company, its affiliated companies, the directors, employees or agents of any such company, and all successors and assigns of any of them. The Company and I waive the right to have a court or jury trial on any arbitrable claim. The Federal Arbitration Act shall govern this arbitration agreement, or if for any reason the FAA does not apply, the arbitration law of the state in which I rendered services to the Company. Notwithstanding any provision of the JAMS Rules, arbitration shall occur on an individual basis only, and a court of competent jurisdiction (and not an arbitrator) shall resolve any dispute about the formation, validity, or enforceability of any provision of this arbitration agreement. I waive the right to initiate, participate in, or recover through, any class or collective action. To the maximum extent permitted by law, the arbitrator shall award the prevailing party its costs and reasonable attorney’s fees; provided, however, that the arbitrator at all times shall apply the law for the shifting of costs and fees that a court would apply to the claim(s) asserted. Nothing in this arbitration agreement prevents me from filing or recovering pursuant to a complaint, charge, or other communication with any federal, state or local governmental or law enforcement agency. This arbitration agreement shall remain in effect notwithstanding the termination of my association with the Company. To opt-out of this paragraph, you must complete an opt-out form prior to your Start Date. Please email hr@wish.com for the form. 

  13.Contingencies. This offer is contingent upon proof of identity and eligibility to work (including by way of an O-1 visa being granted to you) in the United States, which proof must be submitted to the Company. Your continued employment with the Company is contingent upon you remaining authorized to work in the United States for Wish. The Company reserves the right to conduct background, credit and/or reference checks on all of its potential employees. Your job offer, therefore, is contingent upon clearance of such background, credit and/or reference checks, including satisfactory responses to a D&O questionnaire. 

  

   

  We hope that you will accept our offer to join the Company. You may indicate your agreement with these terms and accept this offer by signing and dating this letter agreement and the enclosed exhibit, and returning them to me. This offer, if not accepted, will expire at the end of day on September 8, 2022.  

  	 

   

  Very truly yours,

  ContextLogic Inc.

  /s/ Tanzeen Syed

  Tanzeen Syed

  Chair of the Board of Directors

  	 

  		 

   

  Enclosures

   

   

   

   

  I have read and accept this employment offer:

   

  Jun (Joe) Yan                       

  Name

   

  /s/ Jun Yan                       

  Signature

   

  September 7, 2022

  Date (MM/DD/YYYY)Exhibit
10.1

 

Execution
Version

 

COMMON
STOCK PURCHASE AGREEMENT

 

Dated
as of November 8, 2021

 

by
and between

 

GAUCHO
GROUP HOLDINGS, INC.

 

and

 

TUMIM
STONE CAPITAL LLC

 

    	 

    	 

    

 

Table
of Contents

 

	 	Page
	Article I DEFINITIONS	1
	 	 
	Article
    II PURCHASE AND SALE OF COMMON STOCK	1
	 	Section
    2.1.	Purchase
    and Sale of Stock	1
	 	Section
    2.2.	Closing
    Date; Settlement Dates	2
	 	Section
    2.3.	Initial
    Public Announcements and Required Filings	2
	 	 	 	 
	Article
    III PURCHASE TERMS	3
	 	Section
    3.1.	[Reserved]	3
	 	Section
    3.2.	VWAP
    Purchases	3
	 	Section
    3.3.	Settlement	4
	 	Section
    3.4.	Compliance
    with Rules of Trading Market.	4
	 	Section
    3.5.	Beneficial
    Ownership Limitation	5
	 	 	 	 
	Article
    IV REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE INVESTOR	5
	 	Section
    4.1.	Organization
    and Standing of the Investor	6
	 	Section
    4.2.	Authorization
    and Power	6
	 	Section
    4.3.	No
    Conflicts	6
	 	Section
    4.4.	Investment
    Purpose	7
	 	Section
    4.5.	Accredited
    Investor Status	7
	 	Section
    4.6.	Reliance
    on Exemptions	7
	 	Section
    4.7.	Information	7
	 	Section
    4.8.	No
    Governmental Review	7
	 	Section
    4.9.	No
    General Solicitation	8
	 	Section
    4.10.	Not
    an Affiliate	8
	 	Section
    4.11.	No
    Prior Short Sales	8
	 	Section
    4.12.	Statutory
    Underwriter Status	8
	 	Section
    4.13.	Resales
    of Securities	8
	 	 	 	 
	Article
    V REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY	9
	 	Section
    5.1.	Organization,
    Good Standing and Power	9
	 	Section
    5.2.	Authorization,
    Enforcement	9
	 	Section
    5.3.	Capitalization	9
	 	Section
    5.4.	Issuance
    of Securities	10
	 	Section
    5.5.	No
    Conflicts	10
	 	Section
    5.6.	Commission
    Documents, Financial Statements; Disclosure Controls and Procedures; Internal Controls Over Financial Reporting; Accountants	11
	 	Section
    5.7.	Subsidiaries	13
	 	Section
    5.8.	No
    Material Adverse Effect or Material Adverse Change	13
	 	Section
    5.9.	No
    Undisclosed Liabilities	14
	 	Section
    5.10.	No
    Undisclosed Events or Circumstances	14
	 	Section
    5.11.	Indebtedness;
    Solvency	14
	 	Section
    5.12.	Title
                                            To Assets

                                                         
	15

 

    	i

    	 

    

 

	 	Section
    5.13.	Actions
    Pending	15
	 	Section
    5.14.	Compliance
    With Law; Compliance with Continued Listing Standards	15
	 	Section
    5.15.	Certain
    Fees	15
	 	Section
    5.16.	Disclosure	16
	 	Section
    5.17.	Operation
    of Business	16
	 	Section
    5.18.	Environmental
    Compliance	17
	 	Section
    5.19.	Material
    Agreements	17
	 	Section
    5.20.	Transactions
    With Affiliates	17
	 	Section
    5.21.	Employees;
    Labor Laws	18
	 	Section
    5.22.	[Reserved]	18
	 	Section
    5.23.	Investment
    Company Act Status	18
	 	Section
    5.24.	ERISA	18
	 	Section
    5.25.	Taxes	19
	 	Section
    5.26.	Insurance	19
	 	Section
    5.27.	Exemption
    from Registration	19
	 	Section
    5.28.	No
    General Solicitation or Advertising	20
	 	Section
    5.29.	No
    Integrated Offering	20
	 	Section
    5.30.	Dilutive
    Effect	20
	 	Section
    5.31.	Manipulation
    of Price	20
	 	Section
    5.32.	Securities
    Act	20
	 	Section
    5.33.	Listing
    and Maintenance Requirements; DTC Eligibility	21
	 	Section
    5.34.	Application
    of Takeover Protections	21
	 	Section
    5.35.	No
    Unlawful Payments	21
	 	Section
    5.36.	Money
    Laundering Laws	22
	 	Section
    5.37.	OFAC	22
	 	Section
    5.38.	U.S.
    Real Property Holding Corporation	22
	 	Section
    5.39.	Bank
    Holding Company Act	23
	 	Section
    5.40.	Information
    Technology; Compliance With Data Privacy Laws	23
	 	Section
    5.41.	No
    Disqualification Events	23
	 	Section
    5.42.	Accuracy
    of Certain Summaries and Statements	23
	 	Section
    5.43.	Acknowledgement
    Regarding Investor’s Acquisition of Securities	24
	 	 	 	 
	Article
    VI ADDITIONAL COVENANTS	24
	 	Section
    6.1.	Securities
    Compliance	24
	 	Section
    6.2.	Reservation
    of Common Stock	24
	 	Section
    6.3.	Registration
    and Listing	25
	 	Section
    6.4.	Compliance
    with Laws.	25
	 	Section
    6.5.	Keeping
    of Records and Books of Account; Due Diligence.	26
	 	Section
    6.6.	No
    Frustration; No Variable Rate Transactions.	26
	 	Section
    6.7.	Corporate
    Existence	27
	 	Section
    6.8.	Fundamental
    Transaction	27
	 	Section
    6.9.	Selling
    Restrictions.	27
	 	Section
    6.10.	Effective
    Registration Statement	27
	 	Section
    6.11.	Blue
    Sky	28
	 	Section
    6.12.	Non-Public
    Information	28
	 	Section
    6.13.	Broker/Dealer	28
	 	Section
    6.14.	Disclosure
    Schedule.	29

 

    	ii

    	 

    

 

	 	Section
    6.15.	Delivery
    of Bring Down Opinions and Compliance Certificates Upon Occurrence of Certain Events	29
	 	 	 	 
	Article
    VII CONDITIONS TO CLOSING AND CONDITIONS TO THE SALE AND PURCHASE OF THE SHARES	30
	 	Section
    7.1.	Conditions
    Precedent to Closing	30
	 	Section
    7.2.	Conditions
    Precedent to Commencement	31
	 	Section
    7.3.	Conditions
    Precedent to VWAP Purchases after Commencement Date	34
	 	 	 	 
	Article
    VIII TERMINATION	37
	 	Section
    8.1.	Automatic
    Termination	37
	 	Section
    8.2.	Other
    Termination	37
	 	Section
    8.3.	Effect
    of Termination	38
	 	 	 	 
	Article
    IX INDEMNIFICATION	38
	 	Section
    9.1.	Indemnification
    of Investor	38
	 	Section
    9.2.	Indemnification
    Procedures	39
	 	 	 	 
	Article
    X MISCELLANEOUS	40
	 	Section
    10.1.	Certain
    Fees and Expenses; Commencement Irrevocable Transfer Agent Instructions.	40
	 	Section
    10.2.	Specific
    Enforcement, Consent to Jurisdiction, Waiver of Jury Trial.	41
	 	Section
    10.3.	Entire
    Agreement	41
	 	Section
    10.4.	Notices	41
	 	Section
    10.5.	Waivers	42
	 	Section
    10.6.	Amendments	42
	 	Section
    10.7.	Headings	42
	 	Section
    10.8.	Construction	43
	 	Section
    10.9.	Binding
    Effect	43
	 	Section
    10.10.	No
    Third Party Beneficiaries	43
	 	Section
    10.11.	Governing
    Law	43
	 	Section
    10.12.	Survival	43
	 	Section
    10.13.	Counterparts	43
	 	Section
    10.14.	Publicity	44
	 	Section
    10.15.	Severability	44
	 	Section
    10.16.	Further
    Assurances	44
	 	 	 	 
	Annex
    I. Definitions	 

 

    	iii

    	 

    

 

COMMON
STOCK PURCHASE AGREEMENT

 

This
COMMON STOCK PURCHASE AGREEMENT is made and entered into as of November 8, 2021 (this “Agreement”),
by and between Tumim Stone Capital LLC, a Delaware limited liability company (the “Investor”), and Gaucho Group
Holdings, Inc., a Delaware corporation (the “Company”).

 

RECiTALS

 

WHEREAS,
the parties desire that, upon the terms and subject to the conditions and limitations set forth herein, the Company may issue and sell
to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to the lesser of (i) $44,308,969.30
worth of newly issued shares of the Company’s common stock, par value $0.01 per share (“Common Stock”),
and (ii) the Exchange Cap (to the extent applicable under Section 3.4 hereof);

 

WHEREAS,
such sales of Common Stock by the Company to the Investor will be made in reliance upon the provisions of Section 4(a)(2) of the Securities
Act (“Section 4(a)(2)”) and/or Rule 506(b) of Regulation D promulgated by the Commission under the Securities
Act (“Regulation D”), and upon such other exemption from the registration requirements of the Securities Act
as may be available with respect to any or all of the sales of Common Stock to the Investor to be made hereunder; and

 

WHEREAS,
the parties hereto are concurrently entering into a Registration Rights Agreement in the form attached as Exhibit A hereto
(the “Registration Rights Agreement”), pursuant to which the Company shall register the resale of the Registrable
Securities (as defined in the Registration Rights Agreement), upon the terms and subject to the conditions set forth therein.

 

NOW,
THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:

 

Article
I

DEFINITIONS

 

Capitalized
terms used in this Agreement shall have the meanings ascribed to such terms in Annex I hereto, and hereby made a part hereof,
or as otherwise set forth in this Agreement.

 

Article
II

PURCHASE AND SALE OF COMMON STOCK

 

Section
2.1. Purchase and Sale of Stock. Upon the terms and subject to the conditions of this Agreement, during the Investment Period,
the Company, in its sole discretion, shall have the right, but not the obligation, to issue and sell to the Investor, and the Investor
shall purchase from the Company, up to the lesser of (i) $44,308,969.30 (the “Total Commitment”) in aggregate
gross purchase price of duly authorized, validly issued, fully paid and non-assessable shares of Common Stock and (ii) the Exchange Cap,
to the extent applicable under Section 3.4 (such lesser amount of shares of Common Stock, the “Aggregate Limit”),
by the delivery to the Investor of VWAP Purchase Notices as provided in Article III.

 

    	 

    	 

    

 

Section
2.2. Closing Date; Settlement Dates. This Agreement shall become effective and binding (the “Closing”)
upon (a) the payment of the Investor Expense Reimbursement to the Investor at or prior to the Closing pursuant to Sections 7.1 and 10.1(i),
and (b) the delivery of counterpart signature pages of this Agreement and the Registration Rights Agreement executed by each of the parties
hereto and thereto, and (c) the delivery of all other documents, instruments and writings required to be delivered at the Closing, in
each case as provided in Section 7.1, to the offices of Dorsey & Whitney LLP, 51 West 52nd Street, New York, NY 10019-6119,
at 4:00 p.m., New York City time, on the Closing Date. In consideration of and in express reliance upon the representations, warranties
and covenants contained in, and upon the terms and subject to the conditions of, this Agreement, during the Investment Period the Company
shall issue and sell to the Investor, and the Investor shall purchase from the Company, the Shares in respect of each VWAP Purchase.
The payment for, against simultaneous delivery of, Shares in respect of each VWAP Purchase shall occur in accordance with Section 3.3,
provided that all of the conditions precedent in Article VII shall have been fulfilled at the applicable times set forth in Article
VII.

 

Section
2.3. Initial Public Announcements and Required Filings. The Company shall, within the time period required under the Exchange
Act, file with the Commission a Current Report on Form 8-K describing the material terms of the transactions contemplated by the Transaction
Documents, including, without limitation, attaching as exhibits thereto copies of each of this Agreement, the Registration Rights Agreement
and, if applicable, any press release issued by the Company disclosing the execution of this Agreement by the Company (including all
exhibits thereto, the “Current Report”). The Company shall provide the Investor a reasonable opportunity to
comment on a draft of the Current Report prior to filing the Current Report with the Commission and shall give due consideration to all
such comments. From and after the filing of the Current Report with the Commission, the Company shall have publicly disclosed all material,
nonpublic information delivered to the Investor (or the Investor’s representatives or agents) by the Company, or any of its officers,
directors, employees, agents or representatives (if any) in connection with the transactions contemplated by the Transaction Documents.
The Investor covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company
as described in this Section 2.3, the Investor shall maintain the confidentiality of all disclosures made to it in connection with the
transactions contemplated by the Transaction Documents (including the existence and terms of the transactions), except that the Investor
may disclose the terms of such transactions to its financial, accounting, legal and other advisors (provided that the Investor directs
such Persons to maintain the confidentiality of such information). Not later than 15 calendar days following the Closing Date, the Company
shall file a Form D with respect to the issuance and sale of the Shares in accordance with Regulation D and shall provide a copy thereof
to the Investor promptly after such filing. The Company shall use its commercially reasonable efforts to prepare and, as soon as practicable,
but in no event later than the applicable Filing Deadline, file with the Commission the Initial Registration Statement and any New Registration
Statement covering only the resale by the Investor of the Registrable Securities in accordance with the Securities Act and the Registration
Rights Agreement. At or before 5:30 p.m. (New York City time) on the second (2nd) Trading Day immediately following the Effective
Date of the Initial Registration Statement and any New Registration Statement (or any post-effective amendment thereto), the Company
shall file with the Commission in accordance with Rule 424(b) under the Securities Act the final Prospectus to be used in connection
with sales pursuant to such Registration Statement (or post-effective amendment thereto).

 

    	2

    	 

    

 

Article
III

PURCHASE TERMS

 

Subject
to the satisfaction of the conditions set forth in Article VII, the parties agree as follows:

 

Section
3.1. [Reserved].

 

Section
3.2. VWAP Purchases. Upon the initial satisfaction of all of the conditions set forth in set forth in Section 7.2 (the “Commencement”
and the date of initial satisfaction of all of such conditions, the “Commencement Date”) and from time to time
thereafter, subject to the satisfaction of all of the conditions set forth in Section 7.3 and in this Section 3.2, the Company shall
also have the right, but not the obligation, to direct the Investor, by its delivery to the Investor of a VWAP Purchase Notice on a VWAP
Purchase Exercise Date to purchase the applicable VWAP Purchase Share Amount, not to exceed the applicable VWAP Purchase Maximum Amount,
at the applicable VWAP Purchase Price therefor (as confirmed in the applicable VWAP Purchase Confirmation) in accordance with this Agreement
(each such purchase, a “VWAP Purchase”). The Company may deliver a VWAP Purchase Notice to the Investor on
a VWAP Purchase Exercise Date, so long as (i) at least three (3) Trading Days has elapsed since the Trading Day on which most recent
prior VWAP Purchase Notice was delivered by the Company to the Investor, in each case pursuant to and in accordance with this Agreement,
and (ii) all Shares subject to all prior VWAP Purchase Notices (as applicable) delivered by the Company to the Investor pursuant to this
Agreement have theretofore been received by the Investor as DWAC SharesThe Investor is obligated to accept each VWAP Purchase Notice
prepared and delivered by the Company in accordance with the terms of and subject to the satisfaction of the conditions contained in
this Agreement. If the Company delivers any VWAP Purchase Notice directing the Investor to purchase a VWAP Purchase Share Amount in excess
of the applicable VWAP Purchase Maximum Amount that the Company is then permitted to include in such VWAP Purchase Notice, such VWAP
Purchase Notice shall be void ab initio to the extent of the amount by which the VWAP Purchase Share Amount set forth in such
VWAP Purchase Notice exceeds such applicable VWAP Purchase Maximum Amount, and the Investor shall have no obligation to purchase such
excess Shares in respect of such VWAP Purchase Notice; provided, however, that the Investor shall remain obligated to purchase
the applicable VWAP Purchase Maximum Amount in such VWAP Purchase. At or prior to 9:30 a.m., New York City time, on the Trading Day immediately
following the VWAP Purchase Valuation Period for each VWAP Purchase (the “VWAP Purchase Date”), the Investor
shall provide to the Company a written confirmation for such VWAP Purchase setting forth the applicable VWAP Purchase Share Amount and
the applicable VWAP Purchase Price (both on a per Share basis and the total aggregate VWAP Purchase Price to be paid by the Investor
for such applicable VWAP Purchase Share Amount) for such VWAP Purchase (each, a “VWAP Purchase Confirmation”).
Notwithstanding the foregoing, the Company shall not deliver any VWAP Purchase Notices to the Investor during the PEA Period.

 

    	3

    	 

    

 

Section
3.3. Settlement. The payment for, against simultaneous delivery of, Shares in respect of each VWAP Purchase shall be settled
on the applicable VWAP Purchase Date for such VWAP Purchase. For each VWAP Purchase, the Investor shall pay to the Company an amount
in cash equal to, (i) the product of (A) the total number of Shares purchased by the Investor in such VWAP Purchase (as confirmed in
the applicable VWAP Purchase Confirmation) and (B) the applicable VWAP Purchase Price for such Shares (as confirmed in the applicable
VWAP Purchase Confirmation), in each case as full payment for such Shares, via wire transfer of immediately available funds on the same
Trading Day that the Investor receives such Shares as DWAC Shares in accordance with this Agreement, if all of such Shares are so received
by the Investor before 1:00 p.m., New York City time, or, if such Shares are received by the Investor after 1:00 p.m., New York City
time, then payment therefor shall be made on the Trading Day immediately following the Trading Day on which the Investor has received
all of such Shares as DWAC Shares. If the Company or the Transfer Agent shall fail for any reason, other than a failure of the Investor
or its Broker-Dealer to set up a DWAC and required instructions, to electronically transfer any Shares as DWAC Shares in respect of a
VWAP Purchase within two (2) Trading Days following the receipt by the Company of the applicable purchase price therefor in compliance
with this Section 3.3, and if on or after such Trading Day the Investor purchases (in an open market transaction or otherwise) shares
of Common Stock to deliver in satisfaction of a sale by the Investor of such Shares that the Investor anticipated receiving from the
Company in respect of such VWAP Purchase, then the Company shall, within two (2) Trading Days after the Investor’s request, either
(1) pay cash to the Investor in an amount equal to the Investor’s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased (the “Cover Price”), at which point the Company’s obligation
to deliver such Shares as DWAC Shares shall terminate, or (ii) promptly honor its obligation to deliver to the Investor such Shares as
DWAC Shares and pay cash to the Investor in an amount equal to the excess (if any) of the Cover Price over the total purchase price paid
by the Investor pursuant to this Agreement for all of the Shares to be purchased by the Investor in connection with such VWAP Purchase.
The Company shall not issue any fraction of a share of Common Stock upon any VWAP Purchase. If the issuance would result in the issuance
of a fraction of a share of Common Stock, the Company shall round such fraction of a share of Common Stock up or down to the nearest
whole share. All payments made under this Agreement shall be made in lawful money of the United States of America or wire transfer of
immediately available funds to such account as the Company may from time to time designate by written notice in accordance with the provisions
of this Agreement. Whenever any amount expressed to be due by the terms of this Agreement is due on any day that is not a Trading Day,
the same shall instead be due on the next succeeding day that is a Trading Day.

 

Section
3.4. Compliance with Rules of Trading Market.

 

(a)
Exchange Cap. Subject to Section 3.4(b), the Company shall not issue or sell any shares of Common Stock pursuant to this
Agreement, and the Investor shall not purchase or acquire any shares of Common Stock pursuant to this Agreement, to the extent that after
giving effect thereto, the aggregate number of shares of Common Stock that would be issued pursuant to this Agreement and the transactions
contemplated hereby would exceed 549,648 (representing 19.99% of the shares of Common Stock issued and outstanding immediately prior
to the execution of this Agreement), which number of shares shall be reduced, on a share-for-share basis, by the number of shares of
Common Stock issued or issuable pursuant to any transaction or series of transactions that may be aggregated with the transactions contemplated
by this Agreement under applicable rules of the Trading Market (such maximum number of shares, the “Exchange Cap”),
unless the Company’s stockholders have approved the issuance of Common Stock pursuant to this Agreement in excess of the Exchange
Cap in accordance with the applicable rules of the Trading Market. For the avoidance of doubt, the Company may, but shall be under no
obligation to, request its stockholders to approve the issuance of Common Stock pursuant to this Agreement; provided, that if
such stockholder approval is not obtained, the Exchange Cap shall be applicable for all purposes of this Agreement and the transactions
contemplated hereby at all times during the term of this Agreement (except as set forth in Section 3.4(b)).

 

    	4

    	 

    

 

(b)
At-Market Transaction. Notwithstanding Section 3.4(a) above, the Exchange Cap shall not be applicable for any purposes
of this Agreement and the transactions contemplated hereby, solely to the extent that (and only for so long as) the Average Price shall
equal or exceed the Minimum Price (it being hereby acknowledged and agreed that the Exchange Cap shall be applicable for all purposes
of this Agreement and the transactions contemplated hereby at all other times during the term of this Agreement, unless the stockholder
approval referred to in Section 3.4(a) is obtained).

 

(c)
General. The Company shall not issue or sell any shares of Common Stock pursuant to this Agreement if such issuance or
sale would reasonably be expected to result in (A) a violation of the Securities Act or (B) a breach of the rules of the Trading Market.
The provisions of this Section 3.4 shall be implemented in a manner otherwise than in strict conformity with the terms of this Section
3.4 only if necessary to ensure compliance with the Securities Act and the applicable rules of the Trading Market.

 

Section
3.5. Beneficial Ownership Limitation. Notwithstanding anything to the contrary contained in this Agreement, the Company shall
not issue or sell, and the Investor shall not purchase or acquire, any shares of Common Stock under this Agreement which, when aggregated
with all other shares of Common Stock then beneficially owned by the Investor and its affiliates (as calculated pursuant to Section 13(d)
of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by the Investor of more than 4.99%
of the outstanding shares of Common Stock (the “Beneficial Ownership Limitation”). Upon the written or oral
request of the Investor, the Company shall promptly (but not later than the next business day on which the Transfer Agent is open for
business) confirm orally or in writing to the Investor the number of shares of Common Stock then outstanding. The Investor and the Company
shall each cooperate in good faith in the determinations required under this Section 3.5 and the application of this Section 3.5. The
Investor’s written certification to the Company of the applicability of the Beneficial Ownership Limitation, and the resulting
effect thereof hereunder at any time, shall be conclusive with respect to the applicability thereof and such result absent manifest error.
The provisions of this Section 3.5 shall be construed and implemented in a manner otherwise than in strict conformity with the terms
of this Section 3.5 to the extent necessary to properly give effect to the limitations contained in this Section 3.5.

 

    	5

    	 

    

 

Article
IV

REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE INVESTOR

 

The
Investor hereby makes the following representations, warranties and covenants to the Company:

 

Section
4.1. Organization and Standing of the Investor. The Investor is a limited liability company duly organized, validly existing
and in good standing under the laws of the State of Delaware.

 

Section
4.2. Authorization and Power. The Investor has the requisite limited liability company power and authority to enter into and
perform its obligations under this Agreement and the Registration Rights Agreement and to purchase or acquire the Shares in accordance
with the terms hereof. The execution, delivery and performance by the Investor of this Agreement and the Registration Rights Agreement
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary limited liability
company action, and no further consent or authorization of the Investor, its Board of Directors or its members is required. Each of this
Agreement and the Registration Rights Agreement has been duly executed and delivered by the Investor and constitutes a valid and binding
obligation of the Investor enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership, or similar laws relating to, or affecting
generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application (including
any limitation of equitable remedies).

 

Section
4.3. No Conflicts. The execution, delivery and performance by the Investor of this Agreement and the Registration Rights Agreement
and the consummation by the Investor of the transactions contemplated hereby and thereby do not and shall not (i) result in a violation
of such Investor’s certificate of formation, limited liability company agreement or other applicable organizational instruments,
(ii) conflict with, constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or
give rise to any rights of termination, amendment, acceleration or cancellation of, any material agreement, mortgage, deed of trust,
indenture, note, bond, license, lease agreement, instrument or obligation to which the Investor is a party or is bound, (iii) create
or impose any lien, charge or encumbrance on any property of the Investor under any agreement or any commitment to which the Investor
is party or under which the Investor is bound or under which any of its properties or assets are bound, or (iv) result in a violation
of any federal, state, local or foreign statute, rule, or regulation, or any order, judgment or decree of any court or governmental agency
applicable to the Investor or by which any of its properties or assets are bound or affected, except, in the case of clauses (ii), (iii)
and (iv), for such conflicts, defaults, terminations, amendments, acceleration, cancellations and violations as would not, individually
or in the aggregate, prohibit or otherwise interfere with, in any material respect, the ability of the Investor to enter into and perform
its obligations under this Agreement and the Registration Rights Agreement. The Investor is not required under any applicable federal,
state, local or foreign law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration
with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under this Agreement and
the Registration Rights Agreement or to purchase or acquire the Shares in accordance with the terms hereof; provided, however,
that for purposes of the representation made in this sentence, the Investor is assuming and relying upon the accuracy of the relevant
representations and warranties and the compliance with the relevant covenants and agreements of the Company in the Transaction Documents
to which it is a party.

 

    	6

    	 

    

 

Section
4.4. Investment Purpose. The Investor is acquiring the Shares for its own account, for investment purposes and not with a
view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered under or
exempt from the registration requirements of the Securities Act; provided, however, that by making the representations
herein, the Investor does not agree, or make any representation or warranty, to hold any of the Shares for any minimum or other specific
term and reserves the right to dispose of the Shares at any time in accordance with, or pursuant to, a registration statement filed pursuant
to the Registration Rights Agreement or an applicable exemption under the Securities Act. The Investor does not presently have any agreement
or understanding, directly or indirectly, with any Person to sell or distribute any of the Shares.

 

Section
4.5. Accredited Investor Status. The Investor is an “accredited investor” as that term is defined in Rule 501(a)
of Regulation D.

 

Section
4.6. Reliance on Exemptions. The Investor understands that the Shares are being offered and sold to it in reliance on specific
exemptions from the registration requirements of U.S. federal and state securities laws and that the Company is relying in part upon
the truth and accuracy of, and the Investor’s compliance with, the representations, warranties, agreements, acknowledgments and
understandings of the Investor set forth herein in order to determine the availability of such exemptions and the eligibility of the
Investor to acquire the Shares.

 

Section
4.7. Information. All materials relating to the business, financial condition, management and operations of the Company
and materials relating to the offer and sale of the Shares which have been requested by the Investor have been furnished or otherwise
made available to the Investor or its advisors, including, without limitation, the Commission Documents. The Investor understands that
its investment in the Shares involves a high degree of risk. The Investor is able to bear the economic risk of an investment in the Shares
and has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of a proposed
investment in the Shares. The Investor and its advisors have been afforded the opportunity to ask questions of and receive answers from
representatives of the Company concerning the financial condition and business of the Company and other matters relating to an investment
in the Shares. Neither such inquiries nor any other due diligence investigations conducted by the Investor or its advisors, if any, or
its representatives shall modify, amend or affect the Investor’s right to rely on the Company’s representations and warranties
contained in this Agreement or in any other Transaction Document to which the Company is a party or the Investor’s right to rely
on any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transaction
contemplated hereby (including, without limitation, the opinions of the Company’s counsel delivered pursuant to Sections 7.1(iv)
and 7.2(xvi)). The Investor has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment
decision with respect to its acquisition of the Shares. The Investor understands that it (and not the Company) shall be responsible for
its own tax liabilities that may arise as a result of this investment or the transactions contemplated by this Agreement.

 

Section
4.8. No Governmental Review. The Investor understands that no United States federal or state agency or any other government
or governmental agency has passed on or made any recommendation or endorsement of the Shares or the fairness or suitability of the investment
in the Shares nor have such authorities passed upon or endorsed the merits of the offering of the Shares.

 

    	7

    	 

    

 

Section
4.9. No General Solicitation. The Investor is not purchasing or acquiring the Shares as a result of any form of general solicitation
or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Shares.

 

Section
4.10. Not an Affiliate. The Investor is not an officer, director or an Affiliate of the Company. As of the date of this Agreement,
the Investor does not beneficially own any shares of Common Stock or securities exercisable for or convertible into shares of Common
Stock, and during the Restricted Period, Investor will not acquire beneficial ownership of any shares of the Company’s capital
stock (including shares of Common Stock or securities exercisable for or convertible into shares of Common Stock) other than pursuant
to this Agreement; provided, however, that nothing in this Agreement shall prohibit or be deemed to prohibit the Investor
from purchasing, in an open market transaction or otherwise, shares of Common Stock necessary to make delivery by the Investor in satisfaction
of a sale by the Investor of Shares that the Investor anticipated receiving from the Company in connection with the settlement of a VWAP
Purchase, as applicable, if the Company or its transfer agent shall have failed for any reason (other than a failure of Investor or its
Broker-Dealer to set up a DWAC and required instructions) to electronically transfer all of the Shares subject to such VWAP Purchase,
as applicable, to the Investor on the applicable Settlement Date by crediting the Investor’s or its designated Broker-Dealer’s
account at DTC through its DWAC delivery system in compliance with Section 3.3 of this Agreement.

 

Section
4.11. No Prior Short Sales. At no time prior to the date of this Agreement has any of the Investor, its agents, representatives
or Affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any (i) “short sale” (as such term
is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Stock or (ii) hedging transaction, which establishes a net
short position with respect to the Common Stock.

 

Section
4.12. Statutory Underwriter Status. The Investor acknowledges that it will be disclosed as an “underwriter” and
a “selling stockholder” in each Registration Statement and in any Prospectus contained therein to the extent required by
applicable law and to the extent the Prospectus is related to the resale of Registrable Securities.

 

Section
4.13. Resales of Securities. The Investor represents, warrants and covenants that it will resell such Shares only pursuant
to the Registration Statement in which the resale of such Shares is registered under the Securities Act, in a manner described under
the caption “Plan of Distribution” in such Registration Statement, and in a manner in compliance with all applicable U.S.
federal and state securities laws, rules and regulations, including, without limitation, any applicable prospectus delivery requirements
of the Securities Act.

 

    	8

    	 

    

 

Article
V

REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY

 

Except
as set forth in the disclosure schedule delivered by the Company to the Investor (which is hereby incorporated by reference in, and constitutes
an integral part of, this Agreement) (the “Disclosure Schedule”), the Company hereby makes the following representations,
warranties and covenants to the Investor:

 

Section
5.1. Organization, Good Standing and Power. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise
organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite
power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws
or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in
good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property
owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be,
could not have or reasonably be expected to result in a Material Adverse Effect and no Proceeding has been instituted in any such jurisdiction
revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

 

Section
5.2. Authorization, Enforcement. The Company has the requisite corporate power and authority to enter into and perform its
obligations under each of the Transaction Documents to which it is a party and to issue the Shares in accordance with the terms hereof
and thereof. Except for approvals of the Company’s Board of Directors or a committee thereof as may be required in connection with
any issuance and sale of Shares to the Investor hereunder (which approvals shall be obtained prior to the delivery of any VWAP Purchase
Notice), the execution, delivery and performance by the Company of each of the Transaction Documents to which it is a party and the consummation
by it of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary corporate action, and
no further consent or authorization of the Company, its Board of Directors or its stockholders is required. Each of the Transaction Documents
to which the Company is a party has been duly executed and delivered by the Company and constitutes a valid and binding obligation of
the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting
generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application (including
any limitation of equitable remedies).

 

Section
5.3. Capitalization. The authorized capital stock of the Company and the shares thereof issued and outstanding were
as set forth in the Commission Documents as of the dates reflected therein. All of the outstanding shares of Common Stock have been duly
authorized and validly issued, and are fully paid and non-assessable. Except as set forth in the Commission Documents, this Agreement,
and the Registration Rights Agreement, there are no agreements or arrangements under which the Company is obligated to register the sale
of any securities under the Securities Act. Except as set forth in the Commission Documents, no shares of Common Stock are entitled to
preemptive rights and there are no outstanding debt securities and no contracts, commitments, understandings, or arrangements by which
the Company is or may become bound to issue additional shares of the capital stock of the Company or options, warrants, scrip, rights
to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into or exchangeable
for, any shares of capital stock of the Company other than those issued or granted in the ordinary course of business pursuant to the
Company’s equity incentive and/or compensatory plans or arrangements. Except for customary transfer restrictions contained in agreements
entered into by the Company to sell restricted securities or as set forth in the Commission Documents, the Company is not a party to,
and it has no Knowledge of, any agreement restricting the voting or transfer of any shares of the capital stock of the Company. Except
as set forth in the Commission Documents, there are no securities or instruments containing anti-dilution or similar provisions that
will be triggered by this Agreement or any of the other Transaction Documents or the consummation of the transactions described herein
or therein. The Company has filed with the Commission true and correct copies of the Company’s Certificate of Incorporation as
in effect on the Closing Date (the “Charter”), and the Company’s Bylaws as in effect on the Closing Date
(the “Bylaws”).

 

    	9

    	 

    

 

Section
5.4. Issuance of Securities. The Shares to be issued under this Agreement have been, or with respect to Shares to be purchased
by the Investor pursuant to a particular VWAP Purchase Notice, will be, prior to the delivery to the Investor hereunder of such such
VWAP Purchase Notice, respectively, duly authorized by all necessary corporate action on the part of the Company. The Shares, when issued
and sold against payment therefor in accordance with this Agreement, shall be validly issued and outstanding, fully paid and non-assessable
and free from all liens, charges, taxes, security interests, encumbrances, rights of first refusal, preemptive or similar rights and
other encumbrances with respect to the issue thereof, and the Investor shall be entitled to all rights accorded to a holder of Common
Stock. An aggregate of 1,666,667 shares of Common Stock have been duly authorized and reserved by the Company for issuance as Shares
under this Agreement.

 

Section
5.5. No Conflicts. The execution, delivery and performance by the Company of each of the Transaction Documents to which it
is a party and the consummation by the Company of the transactions contemplated hereby and thereby do not and shall not (i) result in
a violation of any provision of the Company’s Charter or Bylaws, (ii) result in a breach or violation of any of the terms or provisions
of, or constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or give rise to
any rights of termination, amendment, acceleration or cancellation of, any material agreement, mortgage, deed of trust, indenture, note,
bond, license, lease agreement, instrument or obligation to which the Company or any of its Subsidiaries is a party or is bound, (iii)
create or impose a lien, charge or encumbrance on any property or assets of the Company or any of its Subsidiaries under any agreement
or any commitment to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound
or to which any of their respective properties or assets is subject, or (iv) result in a violation of any federal, state, local or foreign
statute, rule, regulation, order, judgment or decree applicable to the Company or any of its Subsidiaries or by which any property or
asset of the Company or any of its Subsidiaries are bound or affected (including federal and state securities laws and regulations and
the rules and regulations of the Trading Market or applicable Eligible Market), except, in the case of clauses (ii), (iii) and (iv),
for such conflicts, defaults, terminations, amendments, acceleration, cancellations, liens, charges, encumbrances and violations as would
not, individually or in the aggregate, have a Material Adverse Effect. Except as specifically contemplated by this Agreement, the Registration
Rights Agreement, the Commission Documents and as required under the Securities Act and any applicable state securities laws or rules
of the Trading Market, the Company is not required under any federal, state, local or foreign law, rule or regulation to obtain any consent,
authorization or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver
or perform any of its obligations under the Transaction Documents to which it is a party, or to issue the Shares to the Investor in accordance
with the terms hereof and thereof (other than such consents, authorizations, orders, filings or registrations as have been obtained or
made prior to the Closing Date); provided, however, that, for purposes of the representation made in this sentence, the
Company is assuming and relying upon the accuracy of the representations and warranties of the Investor in this Agreement and the compliance
by it with its covenants and agreements contained in this Agreement and the Registration Rights Agreement.

 

    	10

    	 

    

 

Section
5.6. Commission Documents, Financial Statements; Disclosure Controls and Procedures; Internal Controls Over Financial Reporting; Accountants.

 

(a)
Except as set forth in the Commission Documents, the Company has timely filed (giving effect to permissible extensions in accordance
with Rule 12b-25 under the Exchange Act) all Commission Documents for the twelve months preceding the date of this Agreement. The Company
has delivered or made available to the Investor via EDGAR or otherwise true and complete copies of the Commission Documents filed with
or furnished to the Commission prior to the Closing Date (including, without limitation, the 2021 Form 10-K). No Subsidiary of the Company
is required to file or furnish any report, schedule, registration, form, statement, information or other document with the Commission.
As of its filing date, each Commission Document filed with or furnished to the Commission prior to the Closing Date (including, without
limitation, the 2021 Form 10-K) complied in all material respects with the requirements of the Securities Act or the Exchange Act, as
applicable, and other federal, state and local laws, rules and regulations applicable to it, and, as of its filing date (or, if amended
or superseded by a filing prior to the Closing Date, on the date of such amended or superseded filing). Each Registration Statement,
on the date it is filed with the Commission, on the date it is declared effective by the Commission, on each VWAP Purchase Exercise Date
shall comply in all material respects with the requirements of the Securities Act (including, without limitation, Rule 415 under the
Securities Act) and shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements therein not misleading, except that this representation and warranty shall not apply
to statements in or omissions from such Registration Statement made in reliance upon and in conformity with information relating to the
Investor furnished to the Company in writing by or on behalf of the Investor expressly for use therein. The Prospectus and each Prospectus
Supplement required to be filed pursuant to this Agreement or the Registration Rights Agreement after the Closing Date, when taken together,
on its date, on each VWAP Purchase Exercise Date, shall comply in all material respects with the requirements of the Securities Act (including,
without limitation, Rule 424(b) under the Securities Act) and shall not contain any untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading, except that this representation and warranty shall not apply to statements in or omissions from
the Prospectus or any Prospectus Supplement made in reliance upon and in conformity with information relating to the Investor furnished
to the Company in writing by or on behalf of the Investor expressly for use therein. Each Commission Document (other than the Initial
Registration Statement or any New Registration Statement, or the Prospectus included therein or any Prospectus Supplement thereto) to
be filed with or furnished to the Commission after the Closing Date and incorporated by reference in the Initial Registration Statement
or any New Registration Statement, or the Prospectus included therein or any Prospectus Supplement thereto required to be filed pursuant
to this Agreement or the Registration Rights Agreement (including, without limitation, the Current Report), when such document is filed
with or furnished to the Commission and, if applicable, when such document becomes effective, as the case may be, shall comply in all
material respects with the requirements of the Securities Act or the Exchange Act, as applicable, and other federal, state and local
laws, rules and regulations applicable to it. The Company has delivered or made available to the Investor via EDGAR or otherwise true
and complete copies of all comment letters and substantive correspondence received by the Company from the Commission relating to the
Commission Documents filed with or furnished to the Commission as of the Closing Date, together with all written responses of the Company
thereto in the form such responses were filed via EDGAR. There are no outstanding or unresolved comments or undertakings in such comment
letters received by the Company from the Commission. The Commission has not issued any stop order or other order suspending the effectiveness
of any registration statement filed by the Company under the Securities Act or the Exchange Act.

 

    	11

    	 

    

 

(b)
The financial statements of the Company included or incorporated by reference in the Commission Documents, together with the related
notes and schedules, comply in all material respects with the requirements of the Securities Act and the Exchange Act and fairly present
the financial condition of the Company and its consolidated subsidiaries as of the dates indicated and the results of operations and
changes in cash flows for the periods therein specified in conformity with generally accepted accounting principles in the United States
(“GAAP”) consistently applied throughout the periods involved; all non-GAAP financial information included
or incorporated by reference in the Commission Documents complies with the requirements of Regulation G and Item 10 of Regulation S-K
under the Securities Act, to the extent applicable; and, except as disclosed in the Commission Documents, there are no material off-balance
sheet arrangements (as defined in Regulation S-K under the Act, Item 303(a)(4)(ii)) or any other relationships with unconsolidated entities
or other persons, that may have a material current or, to the Company’s Knowledge, material future effect on the Company’s
financial condition, results of operations, liquidity, capital expenditures, capital resources or significant components of revenue or
expenses. No other financial statements or schedules are required to be included in the Commission Documents. 

 

(c)
The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)
transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as
necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to
assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required
to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported,
within the time periods specified in the Commission’s rules and forms. The Company’s certifying officers have evaluated the
effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the
most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company
presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness
of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have
been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its
Subsidiaries that have materially adversely affected, or is reasonably likely to materially adversely affect, the internal control over
financial reporting of the Company and its Subsidiaries.

 

    	12

    	 

    

 

(d)
To the Company’s Knowledge, Marcum LLP, which has expressed its opinion with respect to the consolidated financial statements and
schedule as of December 31, 2021 and 2020, and for each of the three years in the period ended December 31, 2021, and management’s
assessment of the effectiveness of internal control over financial reporting as of December 31, 2021, to be filed as a part of the Initial
Registration Statement and incorporated by reference in the Initial Registration Statement and the Prospectus included therein, is (x)
an independent public accounting firm within the meaning of the Act and the Rules and Regulations, (y) a registered public accounting
firm (as defined in Section 2(a)(12) of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”)) and (z)
not in violation of the auditor independence requirements of the Sarbanes-Oxley Act.

 

(e)
There is no failure on the part of the Company or, to the Knowledge of the Company, any of the Company’s directors or officers,
in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act and the rules and regulations
promulgated in connection therewith that are applicable to the Company or its directors or officers in their capacities as directors
or officers of the Company.

 

Section
5.7. Subsidiaries. The Commission Documents set forth each Subsidiary of the Company as of the Closing Date, other than those
that may be omitted pursuant to Item 601 of Regulation S-K, showing its jurisdiction of incorporation or organization, and the Company
does not have any other Subsidiaries as of the Closing Date. No Subsidiary of the Company is currently prohibited, directly or indirectly,
from paying any dividends to the Company, from making any other distribution on such Subsidiary’s capital stock, from repaying
to the Company any loans or advances to such Subsidiary from the Company or from transferring any of such Subsidiary’s property
or assets to the Company or any other Subsidiary of the Company, except as described in or contemplated by the Commission Documents or
as would not reasonably be expected to have a Material Adverse Effect.

 

Section
5.8. No Material Adverse Effect or Material Adverse Change. Except as otherwise disclosed in any Commission Documents, since
the end of the Company’s most recent audited fiscal year: (i) the Company has not experienced or suffered any Material Adverse
Effect, and there exists no current state of facts, condition or event which would have a Material Adverse Effect; (ii) there has not
occurred any material adverse change, or any development that would reasonably be expected to result in a prospective material adverse
change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company from that set forth in the
Commission Documents, including, without limitation, as a result of the recent outbreak of COVID-19, or as a result of any measures intended
to contain the outbreak of COVID-19 imposed by any federal, state, local or foreign government or government agency in any country or
region in which the Company, or any of its agents, consultants, advisors or vendors, has assets or properties or conducts business, including,
without limitation, any limitations, curtailments, suspensions or closures of businesses, business offices or establishments, schools,
properties and other public areas due to quarantines, curfews, travel restrictions, workplace controls, “stay-at-home” orders,
social distancing requirements or guidelines or other public gathering restrictions or limitations; (iii) neither the Company nor any
of its Subsidiaries has incurred any material liability or obligation, direct or contingent, nor entered into any material transaction;
(iv) the Company has not purchased any of its outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution
of any kind on its capital stock other than ordinary and customary dividends; and (v) there has not been any material change in the capital
stock, short-term debt or long-term debt of the Company.

 

    	13

    	 

    

 

Section
5.9. No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims
or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required
to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not
disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective
businesses since December 31, 2021 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse
Effect.

 

Section
5.10. No Undisclosed Events or Circumstances. No event or circumstance has occurred or information exists with respect
to the Company or any of its Subsidiaries or its or their business, properties, liabilities, operations (including results thereof) or
conditions (financial or otherwise), which, under applicable law, rule or regulation, requires public disclosure or announcement by the
Company at or before the Closing but which has not been so publicly announced or disclosed, except for events or circumstances which,
individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.

 

Section
5.11. Indebtedness; Solvency. The 2021 Form 10-K sets forth, as of December 31, 2021, all outstanding secured and unsecured
Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments through such date. For the
purposes of this Agreement, “Indebtedness” shall mean (a) any liabilities for borrowed money or amounts owed
in excess of $500,000 (other than trade accounts payable incurred in the ordinary course of business), (b) all guaranties, endorsements,
indemnities and other contingent obligations in respect of Indebtedness of others in excess of $500,000, whether or not the same are
or should be reflected in the Company’s balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments
for deposit or collection or similar transactions in the ordinary course of business; and (c) the present value of any lease payments
in excess of $500,000 due under leases required to be capitalized in accordance with GAAP. Except as disclosed in the Commission Documents,
there is no existing or continuing default or event of default in respect of any Indebtedness of the Company or any of its Subsidiaries.
The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to Title 11 of the
United States Code or any similar federal or state bankruptcy law or law for the relief of debtors, nor does the Company have any Knowledge
that its creditors intend to initiate involuntary bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings
for relief under Title 11 of the United States Code or any other federal or state bankruptcy law or any law for the relief of debtors.
The Company is financially solvent and is generally able to pay its debts as they become due.

 

    	14

    	 

    

 

Section
5.12. Title To Assets. The Company and each of its Subsidiaries have good and marketable title in fee simple to all real property
and good and marketable title to all personal property owned by them which is material to the business of the Company, in each case free
and clear of all liens, encumbrances and defects except such as are described in the Commission Documents or such as do not materially
affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company and
its Subsidiaries; and any real property and buildings held under lease by the Company and its Subsidiaries are held by it under valid,
subsisting and enforceable leases with such exceptions as are not material and do not interfere in any material respect with the use
made and proposed to be made of such property and buildings by the Company and its Subsidiaries, in each case except as described in
the Commission Documents.

 

Section
5.13. Actions Pending. There are no legal or governmental proceedings pending or, to the Knowledge of the Company, threatened
to which the Company or any of its Subsidiaries are a party or to which any of the properties of the Company or any of its Subsidiaries
is subject (i) other than proceedings accurately described in all material respects in the Commission Documents and proceedings that,
individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect, or on the power or ability of the
Company to perform its obligations under this Agreement and the Registration Rights Agreement or to consummate the transactions contemplated
by the Transaction Documents or (ii) that are required to be described in the Commission Documents and are not so described; and there
are no statutes, regulations, contracts or other documents that are required to be described in the Commission Documents or to be filed
as exhibits to the Commission Documents that are not described or filed as required.

 

Section
5.14. Compliance With Law; Compliance with Continued Listing Standards. The business of the Company and the Subsidiaries has
been and is presently being conducted in compliance with all applicable federal, state, local and foreign governmental laws, rules, regulations
and ordinances, except as set forth in the Commission Documents and except for such non-compliance which, individually or in the aggregate,
would not have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is in violation of any judgment, decree or
order or any statute, ordinance, rule or regulation applicable to the Company or any of its Subsidiaries, and neither the Company nor
any of its Subsidiaries will conduct its business in violation of any of the foregoing, except in all cases for any such violations which
could not, individually or in the aggregate, have a Material Adverse Effect. Except as set forth in the Commission Documents, the Company
has not received any notice of any continuing failure to maintain requirements for continued listing or quotation of its Common Stock
on an applicable Trading Market or in violation of any of the rules, regulations or requirements of any applicable Trading Market, other
than as disclosed to the Investor (including any intended changes with respect to another applicable Trading Market in connection with
any failure to maintain such requirements).

 

Section
5.15. Certain Fees. Except as set forth on Section 5.15 of the Disclosure Schedule, no brokerage or finder’s fees or
commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Investor shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this
Section 5.15 incurred by the Company or its Subsidiaries that may be due or payable in connection with the transactions contemplated
by the Transaction Documents.

 

    	15

    	 

    

 

Section
5.16. Disclosure. The Company confirms that neither it nor any other Person acting on its behalf has provided the Investor
or any of its agents, advisors or counsel with any information that constitutes or could reasonably be expected to constitute material,
nonpublic information concerning the Company or any of its Subsidiaries, other than the existence of the transactions contemplated by
the Transaction Documents. The Company understands and confirms that the Investor will rely on the foregoing representations in effecting
resales of Shares under the Registration Statement. All disclosure provided to Investor regarding the Company and its Subsidiaries, their
businesses and the transactions contemplated by the Transaction Documents (including, without limitation, the representations and warranties
of the Company contained in the Transaction Documents to which it is a party (as modified by the Disclosure Schedule)) furnished in writing
by or on behalf of the Company or any of its Subsidiaries for purposes of or in connection with the Transaction Documents (other than
forward-looking information and projections and information of a general economic nature and general information about the Company’s
industry), taken together, is true and correct in all material respects on the date on which such information is dated or certified,
and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
made therein, in the light of the circumstances under which they were made, not misleading at such time.

 

Section
5.17. Operation of Business.

 

(a)
The Company and its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state or foreign
regulatory authorities necessary to conduct its business, except where the failure to possess such certificates, authorizations or permits
would not, individually or in the aggregate, have a Material Adverse Effect; and neither the Company nor any of its Subsidiaries have
received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which,
singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a Material
Adverse Effect, except as described in the Commission Documents. This Section 5.17(a) does not relate to environmental matters, such
items being the subject of Section 5.18.

 

(b)
The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service
marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary
or required for use in connection with their respective businesses as described in the Commission Documents and which the failure to
so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). None of, and
neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has
expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this
Agreement, except where such action would not reasonably be expected to have a Material Adverse Effect. Other than as specifically described
in the Commission Documents, neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements
included within the Commission Documents, a written notice of a claim or otherwise has any Knowledge that the Company’s products
or planned products as described in the Commission Documents violate or infringe upon the rights of any Person, except as could not have
or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights
are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its
Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties,
except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

    	16

    	 

    

 

Section
5.18. Environmental Compliance. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and
foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater,
land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants,
contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment,
or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice
letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (“Environmental Laws”);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.

 

Section
5.19. Material Agreements Except as set forth in the Commission Documents, neither the Company nor any Subsidiary of the Company
is a party to any written or oral contract, instrument, agreement commitment, obligation, plan or arrangement, a copy of which would
be required to be filed with the Commission as an exhibit to an annual report on Form 10-K (collectively, “Material Agreements”).
Each of the Material Agreements described in the Commission Documents conform in all material respects to the descriptions thereof contained
or incorporated by reference therein. Except as set forth in the Commission Documents, the Company and each of its Subsidiaries have
performed in all material respects all the obligations then required to be performed by them under the Material Agreements, have received
no notice of default or an event of default by the Company or any of its Subsidiaries thereunder and are not aware of any basis for the
assertion thereof, and neither the Company or any of its Subsidiaries nor, to the Knowledge of the Company, any other contracting party
thereto are in default under any Material Agreement now in effect, the result of which would have a Material Adverse Effect. Except as
set forth in the Commission Documents, each of the Material Agreements is in full force and effect, and constitutes a legal, valid and
binding obligation enforceable in accordance with its terms against the Company and/or any of its Subsidiaries and, to the Knowledge
of the Company, each other contracting party thereto, except as such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement
of, creditor’s rights and remedies or by other equitable principles of general application.

 

Section
5.20. Transactions With Affiliates. Except as set forth in the Commission Documents, there are no loans, leases, agreements,
contracts, royalty agreements, management contracts, service arrangements or other continuing transactions exceeding $120,000 between
(a) the Company or any Subsidiary, on the one hand, and (b) any person or entity who would be covered by Item 404(a) of Regulation S-K,
on the other hand. Except as disclosed in the Commission Documents, there are no outstanding amounts payable to or receivable from, or
advances by the Company or any of its Subsidiaries to, and neither the Company nor any of its Subsidiaries is otherwise a creditor of
or debtor to, any beneficial owner of more than 5% of the outstanding shares of Common Stock, or any director, employee or affiliate
of the Company or any of its Subsidiaries, other than (i) reimbursement for reasonable expenses incurred on behalf of the Company or
any of its Subsidiaries or (ii) as part of the normal and customary terms of such person’s employment or service as a director
with the Company or any of its Subsidiaries.

 

    	17

    	 

    

 

Section
5.21. Employees; Labor Laws. No material labor dispute with the employees of the Company exists, except as described in the
Commission Documents, or, to the Knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent
labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that would reasonably be expected
to have a Material Adverse Effect. Neither the Company nor any Subsidiary is in violation of or has received notice of any violation
with respect to any federal or state law relating to discrimination in the hiring, promotion or pay of employees, nor any applicable
federal or state wage and hour laws, nor any state law precluding the denial of credit due to the neighborhood in which a property is
situated, the violation of any of which could reasonably be expected to have a Material Adverse Effect.

 

Section
5.22. [Reserved].

 

Section
5.23. Investment Company Act Status. The Company is not, and as a result of the consummation of the transactions contemplated
by the Transaction Documents and the application of the proceeds from the sale of the Shares as will be set forth in the Prospectus included
in any Registration Statement (and any post-effective amendment thereto) and any Prospectus Supplement thereto filed pursuant to the
Registration Rights Agreement the Company will not be an “investment company” within the meaning of the Investment Company
Act of 1940, as amended.

 

Section
5.24. ERISA. Except as set forth in the Disclosure Schedule, the Company is not a party to an “employee benefit plan,”
as defined in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), which:
(i) is subject to any provision of ERISA and (ii) is or was at any time maintained, administered or contributed to by the Company or
any of its ERISA Affiliates (as defined hereafter). These plans are referred to collectively herein as the “Employee Plans.”
An “ERISA Affiliate” of any person or entity means any other person or entity which, together with that person or entity,
could be treated as a single employer under Section 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended (the “Code”).
Each Employee Plan has been maintained in material compliance with its terms and the requirements of applicable law. No Employee Plan
is subject to Title IV of ERISA. The Commission Documents identify each employment, severance or other similar agreement, arrangement
or policy and each material plan or arrangement required to be disclosed pursuant to the rules and regulations providing for insurance
coverage (including any self-insured arrangements), workers’ compensation, disability benefits, severance benefits, supplemental
unemployment benefits, vacation benefits or retirement benefits, or deferred compensation, profit-sharing, bonuses, stock options, stock
appreciation rights or other forms of incentive compensation, or post-retirement insurance, compensation or benefits, which: (i) is not
an Employee Plan; (ii) is entered into, maintained or contributed to, as the case may be, by the Company or any of its ERISA Affiliates;
and (iii) covers any officer or director or former officer or director of the Company or any of its ERISA Affiliates. These agreements,
arrangements, policies or plans are referred to collectively as “Benefit Arrangements”. Each Benefit Arrangement has been
maintained in material compliance with its terms and with the requirements of applicable law. Except as disclosed in the Commission Documents,
there is no liability in respect of post-retirement health and medical benefits for retired employees of the Company or any of its ERISA
Affiliates, other than medical benefits required to be continued under applicable law. No “prohibited transaction”(as defined
in either Section 406 of ERISA or Section 4975 of the Code) has occurred with respect to any Employee Plan; and each Employee Plan that
is intended to be qualified under Section 401(a) of the Code is so qualified, and nothing has occurred, whether by action or by failure
to act, which could cause the loss of such qualification.

 

    	18

    	 

    

 

Section
5.25. Taxes. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result
in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject,
(ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on
such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim. The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Commission
Documents are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of
such consolidated financial statements. The term “taxes” mean all federal, state, local, foreign, and other net income, gross
income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll,
employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments,
or charges of any kind whatsoever, together with any interest and any penalties, additions to tax, or additional amounts with respect
thereto. The term “returns” means all returns, declarations, reports, statements, and other documents required to be filed
in respect to taxes.

 

Section
5.26. Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged,
including, but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe
that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from
similar insurers as may be necessary to continue its business without a significant increase in cost.

 

Section
5.27. Exemption from Registration. Subject to, and in reliance on, the representations, warranties and covenants made herein
by the Investor, the offer and sale of the Shares in accordance with the terms and conditions of this Agreement is exempt from the registration
requirements of the Securities Act pursuant to Section 4(a)(2) and/or Rule 506(b) of Regulation D; provided, however, that
at the request of and with the express agreements of the Investor (including, without limitation, the representations, warranties and
covenants of Investor set forth in Section 4.9 through 4.13), the Shares to be issued from and after Commencement to or for the benefit
of the Investor pursuant to this Agreement shall be issued to the Investor or its designee only as DWAC Shares and will not bear legends
noting restrictions as to resale of such securities under federal or state securities laws, nor will any such securities be subject to
stop transfer instructions.

 

    	19

    	 

    

 

Section
5.28. No General Solicitation or Advertising. Neither the Company, nor any of its Subsidiaries or Affiliates, nor any Person
acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation
D) in connection with the offer or sale of the Shares.

 

Section
5.29. No Integrated Offering. None of the Company or any of its Affiliates, nor any Person acting on their behalf has, directly
or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require
registration of the issuance of any of the Shares under the Securities Act, whether through integration with prior offerings or otherwise,
or cause this offering of the Shares to require approval of stockholders of the Company under any applicable stockholder approval provisions,
except as pursuant to the rules and regulations of the Trading Market. None of the Company, its Subsidiaries, their Affiliates nor any
Person acting on their behalf will take any action or steps referred to in the preceding sentence that would require registration of
the issuance of any of the Shares under the Securities Act or cause the offering of any of the Shares to be integrated with other offerings.

 

Section
5.30. Dilutive Effect. The Company is aware and acknowledges that issuance of the Shares could cause dilution to existing
stockholders and could significantly increase the outstanding number of shares of Common Stock. The Company further acknowledges that
its obligation to issue the Shares pursuant to the terms of a VWAP Purchase in accordance with this Agreement is, in each case, absolute
and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other stockholders of the
Company.

 

Section
5.31. Manipulation of Price. Neither the Company nor any of its officers, directors or Affiliates has, and, to the Knowledge
of the Company, no Person acting on their behalf has, (i) taken, directly or indirectly, any action designed or intended to cause or
to result in the stabilization or manipulation of the price of any security of the Company, or which caused or resulted in, or which
would in the future reasonably be expected to cause or result in, the stabilization or manipulation of the price of any security of the
Company, in each case to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or paid any compensation
for soliciting purchases of, any of the Shares, except as set forth on Section 5.15 of the Disclosure Schedule, or (iii) paid or agreed
to pay to any Person any compensation for soliciting another to purchase any other securities of the Company. Neither the Company nor
any of its officers, directors or Affiliates will during the term of this Agreement, and, to the Knowledge of the Company, no Person
acting on their behalf will during the term of this Agreement, take any of the actions referred to in the immediately preceding sentence.

 

Section
5.32. Securities Act. Except as set forth in the Disclosure Schedule, the Company has complied and shall comply with all applicable
federal and state securities laws in connection with the offer, issuance and sale of the Shares hereunder, including, without limitation,
the applicable requirements of the Securities Act. Each Registration Statement, upon filing with the Commission and at the time it is
declared effective by the Commission, shall satisfy all of the requirements of the Securities Act to register the resale of the Registrable
Securities included therein by the Investor in accordance with the Registration Rights Agreement on a delayed or continuous basis under
Rule 415 under the Securities Act at then-prevailing market prices, and not fixed prices. The Company is not, and has not previously
been at any time, an issuer identified in, or subject to, Rule 144(i).

 

    	20

    	 

    

 

Section
5.33. Listing and Maintenance Requirements; DTC Eligibility. As of the date of Closing Date, the Common Stock is registered
pursuant to Section 12(b) of the Exchange Act, and the Company has taken no action designed to, or which to its Knowledge is likely to
have the effect of, terminating the registration of the Common Stock under the Exchange Act, nor has the Company received any notification
that the Commission is contemplating terminating such registration. Except as set forth in the Commission Documents, the Company has
not received notice from the Trading Market or any Eligible Market on which the Common Stock is or has been listed or quoted to the effect
that the Company is not in compliance with the listing or maintenance requirements of such Trading Market or Eligible Market, as applicable.
Except as set forth in the Commission Documents, the Company is in compliance with all such listing and maintenance requirements. The
Common Stock is eligible for participation in the DTC book entry system and has shares on deposit at DTC for transferred electronically
to third parties via DTC through its Deposit/Withdrawal at Custodian (“DWAC”) delivery system. The Company
has not received notice from DTC to the effect that a suspension of, or restriction on, accepting additional deposits of the Common Stock,
electronic trading or book-entry services by DTC with respect to the Common Stock is being imposed or is contemplated.

 

Section
5.34. Application of Takeover Protections. The Company and its Board of Directors have taken all necessary action, if any,
in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a
rights agreement) or other similar anti-takeover provision under the Company’s Charter or the laws of its state of incorporation
that is or could become applicable to the Investor as a result of the Investor and the Company fulfilling their respective obligations
or exercising their respective rights under the Transaction Documents (as applicable), including, without limitation, as a result of
the Company’s issuance of the Shares and the Investor’s ownership of the Shares.

 

Section
5.35. No Unlawful Payments. Neither the Company nor any of its Subsidiaries nor any director or officer, nor, to the Knowledge
of the Company, any employee, agent, representative or Affiliate of the Company, has taken within the past five years any action in furtherance
of an offer, payment, promise to pay, or authorization or approval of the payment or giving of money, property, gifts or anything else
of value, directly or indirectly, to any “government official” (including any officer or employee of a government or government-owned
or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any
of the foregoing, or any political party or party official or candidate for political office) to influence official action or secure
an improper advantage (to the extent acting on behalf of or providing services to the Company); and the Company and its Subsidiaries
have conducted their businesses within the past five years in compliance with the U.S. Foreign Corrupt Practices Act of 1977, as amended
(the “FCPA”), any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign
Public Officials in International Business Transactions, signed December 17, 1997, the U.K. Bribery Act 2010 and other applicable anti-corruption,
anti-money laundering and anti-bribery laws, and have instituted and maintain policies and procedures designed to promote and achieve
compliance with such laws and with the representation and warranty contained herein.

 

    	21

    	 

    

 

Section
5.36. Money Laundering Laws. The operations of the Company are and have been conducted at all times within the past five years
in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign
Transactions Reporting Act of 1970, as amended, and the applicable anti-money laundering statutes, including but not limited to, applicable
federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including,
without limitation, Title 18 US. Code section 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering
principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering,
of which the United States is a member and with which designation the United States representative to the group or organization continues
to concur, all as amended, and any Executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any
orders or licenses issued thereunder, of jurisdictions where the Company conducts business, the rules and regulations thereunder and
any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the
“Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws is pending or, to the best knowledge
of the Company, threatened.

 

Section
5.37. OFAC. Neither the Company nor any of its Subsidiaries, nor any director, officer, or employee thereof, nor, to the Company’s
Knowledge, any agent, affiliate or representative of the Company, is a Person that is, or is owned or controlled by a Person that is
(i) the subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control,
the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively,
“Sanctions”), nor (ii) located, organized or resident in a country or territory that is the subject of Sanctions
(including, without limitation, Crimea, Cuba, Iran, North Korea, Sudan and Syria). Neither the Company nor any of its Subsidiaries will,
directly or indirectly, use the proceeds from the sale of Shares under this Agreement, or lend, contribute or otherwise make available
such proceeds to any Subsidiary, joint venture partner or other Person (a) to fund or facilitate any activities or business of or with
any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions, or (b) in any
other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether
as underwriter, advisor, investor or otherwise). For the past five years, neither the Company nor any of its Subsidiaries have knowingly
engaged in, or are now knowingly engaged in, any dealings or transactions with any Person, or in any country or territory, that at the
time of the dealing or transaction is or was the subject of Sanctions.

 

Section
5.38. U.S. Real Property Holding Corporation. Neither the Company nor any of its Subsidiaries is, or has ever been, and so
long as any of the Shares are held by the Investor, shall become a U.S. real property holding corporation within the meaning of Section
897 of the Code.

 

    	22

    	 

    

 

Section
5.39. Bank Holding Company Act. Neither the Company nor any of its Subsidiaries or affiliates is subject to the Bank Holding
Company Act of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve
System (the “Federal Reserve”). Neither the Company nor any of its Subsidiaries or affiliates owns or controls,
directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent
or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the
Company nor any of its Subsidiaries or affiliates exercises a controlling influence over the management or policies of a bank or any
entity that is subject to the BHCA and to regulation by the Federal Reserve.

 

Section
5.40. Information Technology; Compliance With Data Privacy Laws. Except as would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company and its Subsidiaries’
information technology equipment, computers, systems, networks, hardware, software, websites, and databases (collectively, “IT
Systems”) are adequate for, and operate and perform as reasonably required to operate the business of the Company and its
Subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other
malicious code. Except as would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect, the Company and its Subsidiaries have implemented and maintained commercially reasonable physical,
technical and administrative controls, policies, procedures, and safeguards designed to protect their material confidential information
and the integrity, continuous operation, and security of all IT Systems and Personal Data used in connection with their businesses. “Personal
Data” means any information about an individual person that would enable the Company, either alone or in combination with
other information, to identify a natural person. Within the past five years, neither the Company nor its Subsidiaries have experienced
a material information security incident except for those that have been remedied without causing a Material Adverse Effect or a legal
obligation to notify any other Person. The Company and its Subsidiaries are in material compliance with all applicable state and federal
data privacy and security laws of jurisdictions where the Company and its Subsidiaries conduct business.

 

Section
5.41. No Disqualification Events. None of the Company, any of its predecessors, any affiliated issuer, any director, executive
officer, other officer of the Company participating in the offering contemplated hereby, any beneficial owner of 20% or more of the Company’s
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405
under the Securities Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person”)
is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act
(a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under
the Securities Act. The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification
Event.

 

Section
5.42. Accuracy of Certain Summaries and Statements. The statements to be set forth or incorporated by reference, as applicable,
in each Registration Statement (and each post-effective amendment thereto) and the Prospectus included therein under the captions “Description
of Capital Stock,” and in the 2021 Form 10-K under the caption “Certain Relationships and Related Transactions, and Director
Independence”, insofar as they purport to summarize the provisions of the laws and documents referred to therein, are accurate
summaries in all material respects.

 

    	23

    	 

    

 

Section
5.43. Acknowledgement Regarding Investor’s Acquisition of Securities. The Company acknowledges and agrees that the Investor
is acting solely in the capacity of an arm’s-length purchaser with respect to this Agreement and the transactions contemplated
by the Transaction Documents. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of
the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated by the Transaction Documents,
and any advice given by the Investor or any of its representatives or agents in connection therewith is merely incidental to the Investor’s
acquisition of the Shares. The Company further represents to the Investor that the Company’s decision to enter into the Transaction
Documents to which it is a party has been based solely on the independent evaluation of the transactions contemplated thereby by the
Company and its representatives. The Company acknowledges and agrees that the Investor has not made and does not make any representations
or warranties with respect to the transactions contemplated by the Transaction Documents other than those specifically set forth in Article
IV.

 

Article
VI

ADDITIONAL COVENANTS

 

The
Company covenants with the Investor, and the Investor covenants with the Company, as follows, which covenants of one party are for the
benefit of the other party, during the Investment Period (and with respect to the Company, for the period following the termination of
this Agreement specified in Section 8.3 pursuant to and in accordance with Section 8.3):

 

Section
6.1. Securities Compliance. The Company shall notify the Commission and the Trading Market, if and as applicable, in accordance
with their respective rules and regulations, of the transactions contemplated by the Transaction Documents, and shall take all necessary
action, undertake all proceedings and obtain all registrations, permits, consents and approvals for the legal and valid issuance of the
Shares to the Investor in accordance with the terms of the Transaction Documents, as applicable.

 

Section
6.2. Reservation of Common Stock. The Company has available and the Company shall reserve and keep available at all times,
free of preemptive and other similar rights of stockholders, the requisite aggregate number of authorized but unissued shares of Common
Stock to enable the Company to timely effect the issuance, sale and delivery of all Shares to be issued, sold and delivered in respect
of each VWAP Purchase effected under this Agreement, in the case of this clause, at least prior to the delivery by the Company to the
Investor of each VWAP Purchase Notice in connection with such VWAP Purchase. Without limiting the generality of the foregoing, as of
the date of this Agreement the Company has reserved, and as of the Commencement Date shall have continued to reserve, out of its authorized
and unissued Common Stock, 1,666,667 shares of Common Stock solely for the purpose of effecting VWAP Purchases under this Agreement.
The number of shares of Common Stock so reserved for the purpose of effecting VWAP Purchases under this Agreement may be increased from
time to time by the Company from and after the Commencement Date, and such number of reserved shares may be reduced from and after the
Commencement Date only by the number of Shares actually issued, sold and delivered to the Investor pursuant to any VWAP Purchase effected
from and after the Commencement Date pursuant to this Agreement.

 

    	24

    	 

    

 

Section
6.3. Registration and Listing. During the Investment Period, the Company shall use its commercially reasonable efforts to
cause the Common Stock to continue to be registered as a class of securities under Sections 12(b) or 12(g) of the Exchange Act, and to
comply with its reporting and filing obligations under the Exchange Act, and shall not take any action or file any document (whether
or not permitted by the Securities Act or the Exchange Act) to terminate or suspend such registration or to terminate or suspend its
reporting and filing obligations under the Exchange Act or Securities Act, except as permitted herein. The Company shall use its commercially
reasonable efforts to continue the listing and trading of its Common Stock and the listing of the Shares purchased by the Investor hereunder
on the Trading Market and to comply with the Company’s reporting, filing and other obligations under the b rules and regulations
of the Trading Market. The Company shall not take any action which could be reasonably expected to result in the delisting or suspension
of the Common Stock on the Trading Market. If the Company receives any final and non-appealable notice that the listing or quotation
of the Common Stock on the Trading Market shall be terminated on a date certain, the Company shall promptly (and in any case within 24
hours) notify the Investor of such fact in writing and shall use its commercially reasonable efforts to cause the Common Stock to be
listed or quoted on another Eligible Market.

 

Section
6.4. Compliance with Laws.

 

(i)
During the Investment Period, the Company (a) shall comply, and cause each Subsidiary (if any) to comply, with all laws, rules, regulations
and orders applicable to the business and operations of the Company and its Subsidiaries, except as would not have a Material Adverse
Effect and (b) with applicable provisions of the Securities Act and the Exchange Act, including Regulation M thereunder, applicable state
securities or “Blue Sky” laws, and applicable listing rules of the Trading Market or Eligible Market, except as would not,
individually or in the aggregate, prohibit or otherwise interfere with the ability of the Company to enter into and perform its obligations
under this Agreement in any material respect or for Investor to conduct resales of Shares under the Registration Statement in any material
respect. Without limiting the foregoing, neither the Company, nor to the Knowledge of the Company, any of their respective directors,
officers, agents, employees or any other Persons acting on their behalf shall, in connection with the operation of the Company’s
businesses, (1) use any corporate funds for unlawful contributions, payments, gifts or entertainment or to make any unlawful expenditures
relating to political activity to government officials, candidates or members of political parties or organizations, (2) pay, accept
or receive any unlawful contributions, payments, expenditures or gifts, or (3) violate or operate in noncompliance with any export restrictions,
anti-boycott regulations, embargo regulations or other applicable domestic or foreign laws and regulations, including, without limitation,
the FCPA and the Money Laundering Laws.

 

(ii)
The Investor shall comply with all laws, rules, regulations and orders applicable to the performance by it of its obligations under this
Agreement and its investment in the Shares, except as would not, individually or in the aggregate, prohibit or otherwise interfere with
the ability of the Investor to enter into and perform its obligations under this Agreement in any material respect. Without limiting
the foregoing, the Investor shall comply with all applicable provisions of the Securities Act and the Exchange Act, including Regulation
M thereunder, and all applicable state securities or “Blue Sky” laws.

 

    	25

    	 

    

 

Section
6.5. Keeping of Records and Books of Account; Due Diligence.

 

(i)
During the Investment Period, (a) the Company shall keep and cause each Subsidiary to keep adequate records and books of account, in
which complete entries shall be made in accordance with GAAP consistently applied, reflecting all financial transactions of the Company
and its Subsidiaries, and in which, for each fiscal year, all proper reserves for depreciation, depletion, obsolescence, amortization,
taxes, bad debts and other purposes in connection with its business shall be made; and (b) the Company shall maintain a system of internal
accounting controls that (x) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions
and dispositions of the assets of the Company; (y) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of
the Company are being made only in accordance with authorizations of management and directors of the Company; and (z) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that
could have a material effect on the Company’s financial statements (it being acknowledged and agreed that the identification by
the Company and/or its independent registered public accounting firm of any “significant deficiencies” or “material
weaknesses” (each as defined by the Public Company Accounting Oversight Board) in the Company’s internal controls over its
financial reporting shall not, in and of itself, constitute a breach of this Section 6.5(i)).

 

(ii)
Subject to the requirements of Section 6.12, from time to time from and after the Closing Date, the Company shall make available for
inspection and review by the Investor during normal business hours and after reasonable notice, customary documentation reasonably requested
by the Investor and/or its appointed counsel or advisors to conduct due diligence; provided, however, that after the Closing
Date, the Investor’s continued due diligence shall not be a condition precedent to the Company’s right to deliver to the
Investor any any VWAP Purchase Notice or the settlement thereof.

 

Section
6.6. No Frustration; No Variable Rate Transactions.

 

(i)
No Frustration. The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement
or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the
Company to perform its obligations under the Transaction Documents to which it is a party, including, without limitation, the obligation
of the Company to deliver the Shares to the Investor in respect of a VWAP Purchase not later than the applicable VWAP Purchase Date.
For the avoidance of doubt, nothing in this Section 6.6(i) shall in any way limit the Company’s right to terminate this Agreement
in accordance with Section 8.2 (subject in all cases to Section 8.3).

 

(ii)
No Variable Rate Transactions. The Company shall not effect or enter into an agreement to effect any issuance by the Company
or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate
Transaction, other than in connection with an Exempt Issuance or as set forth in the Commission Documents as of the date of this Agreement.
The Investor shall be entitled to seek injunctive relief against the Company and its Subsidiaries to preclude any such issuance, which
remedy shall be in addition to any right to collect damages, without the necessity of showing economic loss and without any bond or other
security being required.

 

    	26

    	 

    

 

Section
6.7. Corporate Existence. The Company shall take all steps necessary to preserve and continue the corporate existence of the
Company; provided, however, that, except as provided in Section 6.8, nothing in this Agreement shall be deemed to prohibit
the Company from engaging in any Fundamental Transaction with another Person. For the avoidance of doubt, nothing in this Section 6.7
shall in any way limit the Company’s right to terminate this Agreement in accordance with Section 8.2 (subject in all cases to
Section 8.3).

 

Section
6.8. Fundamental Transaction. If a VWAP Purchase Notice has been delivered to the Investor and the transactions contemplated
therein have not yet been fully settled in accordance with the terms and conditions of this Agreement, the Company shall not effect any
Fundamental Transaction until the expiration of five (5) Trading Days following the date of full settlement thereof and the issuance
to the Investor of all of the Shares issuable pursuant to the VWAP Purchase to which such VWAP Purchase Notice, respectively, relates.

 

Section
6.9. Selling Restrictions.

 

(i)
Except as expressly set forth below, the Investor covenants that from and after the Closing Date through and including the Trading Day
next following the expiration or termination of this Agreement (the “Restricted Period”), neither the Investor
nor any of its Affiliates nor any entity managed or controlled by the Investor (collectively, the “Restricted Persons”
and each of the foregoing is referred to herein as a “Restricted Person”) shall, directly or indirectly, (x)
engage in any Short Sales involving the Company’s securities or (y) grant any option to purchase, or acquire any right to dispose
of or otherwise dispose for value of, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for
any shares of Common Stock, or enter into any swap, hedge or other similar agreement that transfers, in whole or in part, the economic
risk of ownership of the Common Stock. Notwithstanding the foregoing, it is expressly understood and agreed that nothing contained herein
shall (without implication that the contrary would otherwise be true) prohibit any Restricted Person during the Restricted Period from:
(1) selling “long” (as defined under Rule 200 promulgated under Regulation SHO) the Shares; or (2) selling a number of shares
of Common Stock equal to the number of Shares that such Restricted Person is or may be obligated to purchase under a pending VWAP Purchase
Notice but has not yet taken possession of so long as such Restricted Person (or the Broker-Dealer, as applicable) delivers the Shares
purchased pursuant to such VWAP Purchase Notice (as applicable) to the purchaser thereof or the applicable Broker-Dealer.

 

(ii)
In addition to the foregoing, in connection with any sale of Shares (including any sale permitted by paragraph (i) above), the Investor
shall comply in all respects with all applicable laws, rules, regulations and orders, including, without limitation, the requirements
of the Securities Act and the Exchange Act.

 

Section
6.10. Effective Registration Statement. During the Investment Period, the Company shall use its commercially reasonable efforts
to maintain the continuous effectiveness of the Initial Registration Statement and each New Registration Statement filed with the Commission
under the Securities Act for the applicable Registration Period pursuant to and in accordance with the Registration Rights Agreement.

 

    	27

    	 

    

 

Section
6.11. Blue Sky. The Company shall take such action, if any, as is necessary by the Company in order to obtain an exemption
for or to qualify the Shares for sale by the Company to the Investor pursuant to the Transaction Documents, and at the request of the
Investor, the subsequent resale of Registrable Securities by the Investor, in each case, under applicable state securities or “Blue
Sky” laws and shall provide evidence of any such action so taken to the Investor from time to time following the Closing Date;
provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify
to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 6.11, (y) subject itself
to general taxation in any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction.

 

Section
6.12. Non-Public Information. Neither the Company or any of its Subsidiaries, nor any of their respective directors, officers,
employees or agents shall disclose any material non-public information about the Company to the Investor, unless a simultaneous public
announcement thereof is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the foregoing covenant
by the Company or any of its Subsidiaries, or any of their respective directors, officers, employees and agents (as determined in the
reasonable good faith judgment of the Investor), (i) the Investor shall promptly provide written notice of such breach to the Company
and (ii) after such notice has been provided to the Company and, provided that the Company shall have failed to publicly disclose such
material, non-public information within 24 hours following demand therefor by the Investor, in addition to any other remedy provided
herein or in the other Transaction Documents, the Investor shall have the right to make a public disclosure, in the form of a press release,
public advertisement or otherwise, of such material, non-public information without the prior approval by the Company, any of its Subsidiaries,
or any of their respective directors, officers, employees or agents. The Investor shall not have any liability to the Company, any of
its Subsidiaries, or any of their respective directors, officers, employees, stockholders or agents, for any such disclosure.

 

Section
6.13. Broker/Dealer. The Investor shall use one or more broker-dealers to effectuate all sales, if any, of the Shares that
it may purchase or otherwise acquire from the Company pursuant to the Transaction Documents, as applicable, which (or whom) shall be
unaffiliated with the Investor and not then currently engaged or used by the Company, and a DTC participant (collectively, the “Broker-Dealer”).
The Investor shall, from time to time, provide the Company and its transfer agent with all information regarding the Broker-Dealer reasonably
requested by the Company. The Investor shall be solely responsible for all fees and commissions of the Broker-Dealer, which shall not
exceed customary brokerage fees and commissions and shall be responsible for designating only a DTC participant eligible to receive DWAC
Shares.

 

    	28

    	 

    

 

Section
6.14. Disclosure Schedule.

 

(i)
The Company may, from time to time, update the Disclosure Schedule as may be required to satisfy the conditions set forth in Section
7.2(i) and Section 7.3(i) (to the extent such condition set forth in Section 7.3(i) relates to the condition in Section 7.2(i) as of
a specific VWAP Exercise Purchase Date). For purposes of this Section 6.14, any disclosure made in a schedule to the Compliance Certificate
shall be deemed to be an update of the Disclosure Schedule. Notwithstanding anything in this Agreement to the contrary, no update to
the Disclosure Schedule pursuant to this Section 6.14 shall cure any breach of a representation or warranty of the Company contained
in this Agreement and made prior to the update and shall not affect any of the Investor’s rights or remedies with respect thereto.

 

(ii)
Notwithstanding anything to the contrary contained in the Disclosure Schedule or in this Agreement, the information and disclosure contained
in any Schedule of the Disclosure Schedule shall be deemed to be disclosed and incorporated by reference in any other Schedule of the
Disclosure Schedule as though fully set forth in such Schedule for which applicability of such information and disclosure is readily
apparent on its face. The fact that any item of information is disclosed in the Disclosure Schedule shall not be construed to mean that
such information is required to be disclosed by this Agreement. Except as expressly set forth in this Agreement, such information and
the thresholds (whether based on quantity, qualitative characterization, dollar amounts or otherwise) set forth herein shall not be used
as a basis for interpreting the terms “material” or “Material Adverse Effect” or other similar terms in this
Agreement.

 

Section
6.15. Delivery of Bring Down Opinions and Compliance Certificates Upon Occurrence of Certain Events. Within three (3) Trading
Days immediately following (i) the end of each PEA Period, if the Company is required under the Securities Act to file with the Commission
(A) a post-effective amendment to the Initial Registration Statement required to be filed by the Company with the Commission pursuant
to Section 2(a) of the Registration Rights Agreement, (B) a New Registration Statement required to be filed by the Company with the Commission
pursuant to Section 2(c) of the Registration Rights Agreement, or (C) a post-effective amendment to a New Registration Statement required
to be filed by the Company with the Commission pursuant to Section 2(c) of the Registration Rights Agreement, in each case with respect
to a fiscal year ending after the Commencement Date, to register the resale of Shares by the Investor under the Securities Act pursuant
to this Agreement and the Registration Rights Agreement, and (ii) the date the Company files with the Commission (A) a Prospectus Supplement
to the Prospectus contained in the Initial Registration Statement or any New Registration Statement under the Securities Act, (B) an
annual report on Form 10-K under the Exchange Act with respect to a fiscal year ending after the Commencement Date, (C) an amendment
on Form 10-K/A to an annual report on Form 10-K under the Exchange Act with respect to a fiscal year ending after the Commencement Date,
which contains amended material financial information (or a restatement of material financial information) or an amendment to other material
information contained in a previously filed Form 10-K, and (D) a Commission Document under the Exchange Act (other than those referred
to in clauses (ii)(A) and (ii)(B) of this Section 6.15), which contains amended material financial information (or a restatement of material
financial information) or an amendment to other material information contained or incorporated by reference in the Initial Registration
Statement, any New Registration Statement, or the Prospectus or any Prospectus Supplement contained in the Initial Registration Statement
or any New Registration Statement (it being hereby acknowledged and agreed that the filing by the Company with the Commission of a quarterly
report on Form 10-Q that includes only updated financial information as of the end of the Company’s most recent fiscal quarter
shall not, in and of itself, constitute an “amendment” or “restatement” for purposes of clause (ii) of this Section
6.15), in each case of this clause (ii) if the Company is not also then required under the Securities Act to file a post-effective amendment
to the Initial Registration Statement, any New Registration Statement or a post-effective amendment to any New Registration Statement,
in each case with respect to a fiscal year ending after the Commencement Date, to register the resale of Shares by the Investor under
the Securities Act pursuant to this Agreement and the Registration Rights Agreement, and in any case of this clause (ii), not more than
once per calendar quarter, the Company shall (I) deliver to the Investor a Compliance Certificate, dated such date, and (II) cause to
be furnished to the Investor an opinion “bring down” from outside counsel to the Company substantially in the form mutually
agreed to by the Company and the Investor prior to the date of this Agreement, modified, as necessary, to relate to such Registration
Statement or post-effective amendment, or the Prospectus contained therein as then amended or supplemented by such Prospectus Supplement,
as applicable (each such opinion, a “Bring Down Opinion”).

 

    	29

    	 

    

 

Article
VII

CONDITIONS TO CLOSING AND CONDITIONS TO THE SALE AND

PURCHASE OF THE SHARES

 

Section
7.1. Conditions Precedent to Closing. The Closing is subject to the satisfaction of each of the conditions set forth in this
Section 7.1 on the Closing Date.

 

(i)
Accuracy of the Investor’s Representations and Warranties. The representations and warranties of the Investor contained
in this Agreement (a) that are not qualified by “materiality” shall be true and correct in all material respects as of the
Closing Date, except to the extent such representations and warranties are as of another date, in which case, such representations and
warranties shall be true and correct in all material respects as of such other date and (b) that are qualified by “materiality”
shall be true and correct as of the Closing Date, except to the extent such representations and warranties are as of another date, in
which case, such representations and warranties shall be true and correct as of such other date.

 

(ii)
Accuracy of the Company’s Representations and Warranties. The representations and warranties of the Company contained
in this Agreement (a) that are not qualified by “materiality” or “Material Adverse Effect” shall be true and
correct in all material respects as of the Closing Date, except to the extent such representations and warranties are as of another date,
in which case, such representations and warranties shall be true and correct in all material respects as of such other date and (b) that
are qualified by “materiality” or “Material Adverse Effect” shall be true and correct as of the Closing Date,
except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall
be true and correct as of such other date.

 

(iii)
Payment of Investor Expense Reimbursement. On or prior to the Closing Date, the Company shall have paid by wire transfer
of immediately available funds to an account designated by the Investor on or prior to the date hereof, the Investor Expense Reimbursement
in accordance with Section 10.1(i), all of which Investor Expense Reimbursement shall be fully earned and non-refundable as of the Closing
Date, regardless of whether any VWAP Purchases are made or settled hereunder or any subsequent termination of this Agreement.

 

(iv)
Closing Deliverables. At the Closing, counterpart signature pages of this Agreement and the Registration Rights Agreement
executed by each of the parties hereto shall be delivered as provided in Section 2.2. Simultaneously with the execution and delivery
of this Agreement and the Registration Rights Agreement, the Investor’s counsel shall have received (a) the opinions of outside
counsel to the Company, dated the Closing Date, in the forms mutually agreed to by the Company and the Investor prior to the date of
this Agreement, and (b) the closing certificate from the Company, dated the Closing Date, in the form of Exhibit B hereto.

 

    	30

    	 

    

 

Section
7.2. Conditions Precedent to Commencement. The right of the Company to commence delivering VWAP Purchase Notices under this
Agreement, and the obligation of the Investor to accept VWAP Purchase Notices delivered to the Investor by the Company under this Agreement,
are subject to the initial satisfaction, at Commencement, of each of the conditions set forth in this Section 7.2.

 

(i)
Accuracy of the Company’s Representations and Warranties. The representations and warranties of the Company contained
in this Agreement (a) that are not qualified by “materiality” or “Material Adverse Effect” shall have been true
and correct in all material respects when made and shall be true and correct in all material respects as of the Commencement Date with
the same force and effect as if made on such date, except to the extent such representations and warranties are as of another date, in
which case, such representations and warranties shall be true and correct in all material respects as of such other date and (b) that
are qualified by “materiality” or “Material Adverse Effect” shall have been true and correct when made and shall
be true and correct as of the Commencement Date with the same force and effect as if made on such date, except to the extent such representations
and warranties are as of another date, in which case, such representations and warranties shall be true and correct as of such other
date.

 

(ii)
Performance of the Company. The Company shall have performed, satisfied and complied in all material respects with all
covenants, agreements and conditions required by this Agreement and the Registration Rights Agreement to be performed, satisfied or complied
with by the Company at or prior to the Commencement. The Company shall deliver to the Investor on the Commencement Date the compliance
certificate substantially in the form attached hereto as Exhibit C (the “Compliance Certificate”).

 

(iii)
Initial Registration Statement Effective. The Initial Registration Statement covering the resale by the Investor of the
Registrable Securities included therein required to be filed by the Company with the Commission pursuant to Section 2(a) of the Registration
Rights Agreement shall have been declared effective under the Securities Act by the Commission, and the Investor shall be permitted to
utilize the Prospectus therein to resell all of the Shares included in such Prospectus.

 

(iv)
No Material Notices. None of the following events shall have occurred and be continuing: (a) receipt of any request by
the Commission or any other federal or state governmental authority for any additional information relating to the Initial Registration
Statement, the Prospectus contained therein or any Prospectus Supplement thereto, or for any amendment of or supplement to the Initial
Registration Statement, the Prospectus contained therein or any Prospectus Supplement thereto; (b) the issuance by the Commission or
any other federal or state governmental authority of any stop order suspending the effectiveness of the Initial Registration Statement
or prohibiting or suspending the use of the Prospectus contained therein or any Prospectus Supplement thereto, or of the suspension of
qualification or exemption from qualification of the Shares for offering or sale in any jurisdiction, or the initiation or contemplated
initiation of any proceeding for such purpose; or (c) the occurrence of any event or the existence of any condition or state of facts,
which makes any statement of a material fact made in the Initial Registration Statement, the Prospectus contained therein or any Prospectus
Supplement thereto untrue or which requires the making of any additions to or changes to the statements then made in the Initial Registration
Statement, the Prospectus contained therein or any Prospectus Supplement thereto in order to state a material fact required by the Securities
Act to be stated therein or necessary in order to make the statements then made therein (in the case of the Prospectus or any Prospectus
Supplement, in light of the circumstances under which they were made) not misleading, or which requires an amendment to the Initial Registration
Statement or a supplement to the Prospectus contained therein or any Prospectus Supplement thereto to comply with the Securities Act
or any other law. The Company shall have no Knowledge of any event that could reasonably be expected to have the effect of causing the
suspension of the effectiveness of the Initial Registration Statement or the prohibition or suspension of the use of the Prospectus contained
therein or any Prospectus Supplement thereto in connection with the resale of the Registrable Securities by the Investor.

 

    	31

    	 

    

 

(v)
Other Commission Filings. The Current Report and the Form D shall have been filed with the Commission as required pursuant
to Section 2.3. The final Prospectus included in the Initial Registration Statement shall have been filed with the Commission prior to
Commencement in accordance with Section 2.3 and the Registration Rights Agreement. All reports, schedules, registrations, forms, statements,
information and other documents required to have been filed by the Company with the Commission pursuant to the reporting requirements
of the Exchange Act, including all material required to have been filed pursuant to Section 13(a) or 15(d) of the Exchange Act, prior
to Commencement shall have been filed with the Commission.

 

(vi)
No Suspension of Trading in or Notice of Delisting of Common Stock. Trading in the Common Stock shall not have been suspended
by the Commission, the Trading Market or the FINRA (except for any suspension of trading of limited duration agreed to by the Company,
which suspension shall be terminated prior to the Commencement Date), the Company shall not have received any final and non-appealable
notice that the listing or quotation of the Common Stock on the Trading Market shall be terminated on a date certain (unless, prior to
such date certain, the Common Stock is listed or quoted on any other Eligible Market), nor shall there have been imposed any suspension
of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by DTC with respect
to the Common Stock that is continuing, the Company shall not have received any notice from DTC to the effect that a suspension of, or
restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by DTC with respect to the
Common Stock is being imposed or is contemplated (unless, prior to such suspension or restriction, DTC shall have notified the Company
in writing that DTC has determined not to impose any such suspension or restriction).

 

(vii)
Compliance with Laws. The Company shall have complied with all applicable federal, state and local governmental laws, rules,
regulations and ordinances in connection with the execution, delivery and performance of this Agreement and the other Transaction Documents
to which it is a party and the consummation of the transactions contemplated hereby and thereby, including, without limitation, the Company
shall have obtained all permits and qualifications required by any applicable state securities or “Blue Sky” laws for the
offer and sale of the Shares by the Company to the Investor and the subsequent resale of the Registrable Securities by the Investor (or
shall have the availability of exemptions therefrom).

 

    	32

    	 

    

 

(viii)
No Injunction. No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated,
threatened or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of or which
would materially modify or delay any of the transactions contemplated by the Transaction Documents.

 

(ix)
No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any court or governmental authority
shall have been commenced, and no inquiry or investigation by any governmental authority shall have been commenced, against the Company
or any Subsidiary, or any of the officers, directors or affiliates of the Company or any Subsidiary, seeking to restrain, prevent or
change the transactions contemplated by the Transaction Documents, or seeking material damages in connection with such transactions.

 

(x)
Listing of Securities. All of the Shares that have been and may be issued pursuant to this Agreement shall have been approved
for listing or quotation on the Trading Market as of the Commencement Date, subject only to notice of issuance.

 

(xi)
No Material Adverse Effect. No condition, occurrence, state of facts or event constituting a Material Adverse Effect shall
have occurred and be continuing.

 

(xii)
No Bankruptcy Proceedings. No Person shall have commenced a proceeding against the Company pursuant to or within the meaning
of any Bankruptcy Law. The Company shall not have, pursuant to or within the meaning of any Bankruptcy Law, (a) commenced a voluntary
case, (b) consented to the entry of an order for relief against it in an involuntary case, (c) consented to the appointment of a Custodian
of the Company or for all or substantially all of its property, or (d) made a general assignment for the benefit of its creditors. A
court of competent jurisdiction shall not have entered an order or decree under any Bankruptcy Law that (I) is for relief against the
Company in an involuntary case, (II) appoints a Custodian of the Company or for all or substantially all of its property, or (III) orders
the liquidation of the Company or any of its Subsidiaries.

 

(xiii)
[Reserved].

 

(xiv)
Delivery of Commencement Irrevocable Transfer Agent Instructions and Notice of Effectiveness. The Commencement Irrevocable
Transfer Agent Instructions shall have been executed by the Company and delivered to acknowledged in writing by the Company’s transfer
agent, and the Notice of Effectiveness relating to the Initial Registration Statement shall have been executed by the Company’s
outside counsel and delivered to the Company’s transfer agent, in each case directing the Company’s transfer agent to issue
to the Investor or its designated Broker-Dealer all of the Shares included in the Initial Registration Statement as DWAC Shares in accordance
with this Agreement and the Registration Rights Agreement.

 

    	33

    	 

    

 

(xv)
Reservation of Shares. As of the Commencement Date, the Company shall have reserved out of its authorized and unissued
Common Stock, 1,666,667 shares of Common Stock solely for the purpose of effecting VWAP Purchases under this Agreement.

 

(xvi)
Opinions and Bring-Down Opinions of Company Counsel. On the Commencement Date, the Investor shall have received the opinions,
bring-down opinions and negative assurances from outside counsel to the Company, dated the Commencement Date, in the forms mutually agreed
to by the Company and the Investor prior to the date of this Agreement.

 

Section
7.3. Conditions Precedent to VWAP Purchases after Commencement Date. The right of the Company to deliver VWAP Purchase Notices
under this Agreement after the Commencement Date, and the obligation of the Investor to accept VWAP Purchase Notices under this Agreement
after the Commencement Date, are subject to the satisfaction of each of the conditions set forth in this Section 7.3 at each VWAP Purchase
Exercise Date after the Commencement Date.

 

(i)
Satisfaction of Certain Prior Conditions. Each of the conditions set forth in subsections (i), (ii), and (vii) through
(xiii) set forth in Section 7.2 shall be satisfied on each VWAP Purchase Exercise Date after the Commencement Date (with the terms “Commencement”
and “Commencement Date” in the conditions set forth in subsections (i) and (ii) of Section 7.2 replaced with “applicable
VWAP Purchase Exercise Date”); provided, however, that the Company shall not be required to deliver the Compliance
Certificate after the Commencement Date, except as provided in Section 6.15 and Section 7.3(v).

 

(ii)
Initial Registration Statement Effective. The Initial Registration Statement covering the resale by the Investor of the
Registrable Securities included therein filed by the Company with the Commission pursuant to Section 2(a) of the Registration Rights
Agreement, and any post-effective amendment thereto required to be filed by the Company with the Commission after the Commencement Date
and prior to the applicable VWAP Purchase Exercise Date (as applicable) pursuant to the Registration Rights Agreement, in each case shall
have been declared effective under the Securities Act by the Commission and shall remain effective for the applicable Registration Period
(as defined in the Registration Rights Agreement), and the Investor shall be permitted to utilize the Prospectus therein, and any Prospectus
Supplement thereto, to resell (a) all of the Shares included in the Initial Registration Statement, and any post-effective amendment
thereto, that have been issued and sold to the Investor hereunder pursuant to all VWAP Purchase Notices (as applicable) delivered by
the Company to the Investor prior to such applicable VWAP Purchase Exercise Date (as applicable), respectively, and (b) all of the Shares
included in the Initial Registration Statement, and any post-effective amendment thereto, that are issuable pursuant to the applicable
VWAP Purchase Notice (as applicable) delivered by the Company to the Investor with respect to a VWAP Purchase to be effected hereunder
on such applicable VWAP Purchase Exercise Date.

 

    	34

    	 

    

 

(iii)
Any Required New Registration Statement Effective. Any New Registration Statement covering the resale by the Investor of
the Registrable Securities included therein, and any post-effective amendment thereto, required to be filed by the Company with the Commission
pursuant to the Registration Rights Agreement after the Commencement Date and prior to the applicable VWAP Purchase Exercise Date, in
each case shall have been declared effective under the Securities Act by the Commission and shall remain effective for the applicable
Registration Period, and the Investor shall be permitted to utilize the Prospectus therein, and any Prospectus Supplement thereto, to
resell (a) all of the Shares included in such New Registration Statement, and any post-effective amendment thereto, that have been issued
and sold to the Investor hereunder pursuant to all VWAP Purchase Notices delivered by the Company to the Investor prior to such applicable
VWAP Purchase Exercise Date (as applicable), respectively, and (b) all of the Shares included in such new Registration Statement, and
any post-effective amendment thereto, that are issuable pursuant to the applicable VWAP Purchase Notice delivered by the Company to the
Investor with respect to a VWAP Purchase, respectively, to be effected hereunder on such applicable VWAP Purchase Exercise Date.

 

(iv)
Delivery of Subsequent Irrevocable Transfer Agent Instructions and Notice of Effectiveness. With respect to any post-effective
amendment to the Initial Registration Statement, any New Registration Statement or any post-effective amendment to any New Registration
Statement, in each case declared effective by the Commission after the Commencement Date, the Company shall have delivered or caused
to be delivered to its transfer agent (a) irrevocable instructions in the form substantially similar to the Commencement Irrevocable
Transfer Agent Instructions executed by the Company and acknowledged in writing by the Company’s transfer agent and (b) the Notice
of Effectiveness, in each case modified as necessary to refer to such Registration Statement or post-effective amendment and the Registrable
Securities included therein, to issue the Registrable Securities included therein as DWAC Shares in accordance with the terms of this
Agreement and the Registration Rights Agreement.

 

(v)
No Material Notices. None of the following events shall have occurred and be continuing: (a) receipt of any request by
the Commission or any other federal or state governmental authority for any additional information relating to the Initial Registration
Statement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus
contained in any of the foregoing or any Prospectus Supplement thereto, or for any amendment of or supplement to the Initial Registration
Statement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus
contained in any of the foregoing or any Prospectus Supplement thereto; (b) the issuance by the Commission or any other federal or state
governmental authority of any stop order suspending the effectiveness of the Initial Registration Statement or any post-effective amendment
thereto, any New Registration Statement or any post-effective amendment thereto, or prohibiting or suspending the use of the Prospectus
contained in any of the foregoing or any Prospectus Supplement thereto, or of the suspension of qualification or exemption from qualification
of the Shares for offering or sale in any jurisdiction, or the initiation or contemplated initiation of any proceeding for such purpose;
or (c) the occurrence of any event or the existence of any condition or state of facts, which makes any statement of a material fact
made in the Initial Registration Statement or any post-effective amendment thereto, any New Registration Statement or any post-effective
amendment thereto, or the Prospectus contained in any of the foregoing or any Prospectus Supplement thereto untrue or which requires
the making of any additions to or changes to the statements then made in the Initial Registration Statement or any post-effective amendment
thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained in any of the foregoing
or any Prospectus Supplement thereto in order to state a material fact required by the Securities Act to be stated therein or necessary
in order to make the statements then made therein (in the case of the Prospectus or any Prospectus Supplement, in light of the circumstances
under which they were made) not misleading, or which requires an amendment to the Initial Registration Statement or any post-effective
amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained in any of the
foregoing or any Prospectus Supplement thereto to comply with the Securities Act or any other law (other than the transactions contemplated
by the applicable VWAP Purchase Notice, delivered by the Company to the Investor with respect to a VWAP Purchase, to be effected hereunder
on such applicable VWAP Purchase Exercise Date, as applicable, and the settlement thereof). The Company shall have no Knowledge of any
event that could reasonably be expected to have the effect of causing the suspension of the effectiveness of the Initial Registration
Statement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the prohibition
or suspension of the use of the Prospectus contained in any of the foregoing or any Prospectus Supplement thereto in connection with
the resale of the Registrable Securities by the Investor.

 

    	35

    	 

    

 

(vi)
Other Commission Filings. The final Prospectus included in any post-effective amendment to the Initial Registration Statement,
and any Prospectus Supplement thereto, required to be filed by the Company with the Commission pursuant to Section 2.3 and the Registration
Rights Agreement after the Commencement Date and prior to the applicable VWAP Purchase Exercise Date (as applicable), shall have been
filed with the Commission in accordance with Section 2.3 and the Registration Rights Agreement. The final Prospectus included in any
New Registration Statement and in any post-effective amendment thereto, and any Prospectus Supplement thereto, required to be filed by
the Company with the Commission pursuant to Section 2.3 and the Registration Rights Agreement after the Commencement Date and prior to
the applicable VWAP Purchase Exercise Date, shall have been filed with the Commission in accordance with Section 2.3 and the Registration
Rights Agreement. All reports, schedules, registrations, forms, statements, information and other documents required to have been filed
by the Company with the Commission pursuant to the reporting requirements of the Exchange Act, including all material required to have
been filed pursuant to Section 13(a) or 15(d) of the Exchange Act, after the Commencement Date and prior to the applicable VWAP Purchase
Exercise Date, shall have been filed with the Commission and, if any Registrable Securities are covered by a Registration Statement on
Form S-3, such filings shall have been made within the applicable time period prescribed for such filing under the Exchange Act.

 

(vii)
No Suspension of Trading in or Notice of Delisting of Common Stock. Trading in the Common Stock shall not have been suspended
by the Commission, the Trading Market or the FINRA (except for any suspension of trading of limited duration agreed to by the Company,
which suspension shall be terminated prior to the applicable VWAP Purchase Exercise Date, as applicable), the Company shall not have
received any final and non-appealable notice that the listing or quotation of the Common Stock on the Trading Market shall be terminated
on a date certain (unless, prior to such date certain, the Common Stock is listed or quoted on any other Eligible Market), nor shall
there have been imposed any suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or
book-entry services by DTC with respect to the Common Stock that is continuing, the Company shall not have received any notice from DTC
to the effect that a suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry
services by DTC with respect to the Common Stock is being imposed or is contemplated (unless, prior to such suspension or restriction,
DTC shall have notified the Company in writing that DTC has determined not to impose any such suspension or restriction).

 

    	36

    	 

    

 

(viii)
Certain Limitations. The issuance and sale of the Shares issuable pursuant to the applicable VWAP Purchase Notice shall
not (a) exceed the VWAP Purchase Maximum Amount, (b) cause the Aggregate Limit or the Beneficial Ownership Limitation to be exceeded,
or (c) cause the Exchange Cap (to the extent applicable under Section 3.4) to be exceeded, unless in the case of this clause (c), unless
the Company’s stockholders have theretofore approved the issuance of Common Stock under this Agreement in excess of the Exchange
Cap in accordance with the applicable rules of the Trading Market.

 

(ix)
Shares Authorized and Delivered. All of the Shares issuable pursuant to the applicable VWAP Purchase Notice shall have
been duly authorized by all necessary corporate action of the Company. The Company shall have delivered all Shares relating to all prior
VWAP Purchase Notices as DWAC Shares.

 

(x)
Opinions and Bring-Down Opinions of Company Counsel. The Investor shall have received (a) all Bring Down Opinions from
the Company’s outside counsel for which the Company was obligated to instruct its outside counsel to deliver to the Investor prior
to the applicable VWAP Purchase Exercise Date and (b) all Compliance Certificates from the Company that the Company was obligated to
deliver to the Investor prior to the applicable VWAP Purchase Exercise Date, in each case in accordance with Section 6.15.

 

Article
VIII

TERMINATION

 

Section
8.1. Automatic Termination. Unless earlier terminated as provided hereunder, this Agreement shall terminate automatically
on the earliest to occur of (i) the first day of the month next following the 36-month anniversary of the Effective Date of the Initial
Registration Statement (it being hereby acknowledged and agreed that such term may not be extended by the parties hereto), (ii) the date
on which the Investor shall have purchased the Total Commitment worth of Shares pursuant to this Agreement, (iii) the date on which the
Common Stock shall have failed to be listed or quoted on the Trading Market or any other Eligible Market, and (iv) the date on which,
pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding
against the Company, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a
general assignment for the benefit of its creditors.

 

Section
8.2. Other Termination. Subject to Section 8.3, the Company may terminate this Agreement after the Commencement Date effective
upon ten (10) Trading Days’ prior written notice to the Investor in accordance with Section 10.4; provided, however,
that (i) the Company shall have paid all fees and amounts to the Investor’s counsel required to be paid pursuant to Section 10.1
of this Agreement prior to such termination, and (ii) prior to issuing any press release, or making any public statement or announcement,
with respect to such termination, the Company shall consult with the Investor and its counsel on the form and substance of such press
release or other disclosure. Subject to Section 8.3, this Agreement may be terminated at any time by the mutual written consent of the
parties, effective as of the date of such mutual written consent unless otherwise provided in such written consent. Subject to Section
8.3, the Investor shall have the right to terminate this Agreement effective upon ten (10) Trading Days’ prior written notice to
the Company in accordance with Section 10.4, if: (a) any condition, occurrence, state of facts or event constituting a Material Adverse
Effect has occurred and is continuing; (b) a Fundamental Transaction shall have occurred; (c) the Initial Registration Statement and
any New Registration Statement is not filed by the applicable Filing Deadline therefor or declared effective by the Commission by the
applicable Effectiveness Deadline (as defined in the Registration Rights Agreement) therefor, or the Company is otherwise in breach or
default in any material respect under any of the other provisions of the Registration Rights Agreement, and, if such failure, breach
or default is capable of being cured, such failure, breach or default is not cured within 10 Trading Days after notice of such failure,
breach or default is delivered to the Company pursuant to Section 10.4; (d) while a Registration Statement, or any post-effective amendment
thereto, is required to be maintained effective pursuant to the terms of the Registration Rights Agreement and the Investor holds any
Registrable Securities, the effectiveness of such Registration Statement, or any post-effective amendment thereto, lapses for any reason
(including, without limitation, the issuance of a stop order by the Commission) or such Registration Statement or any post-effective
amendment thereto, the Prospectus contained therein or any Prospectus Supplement thereto otherwise becomes unavailable to the Investor
for the resale of all of the Registrable Securities included therein in accordance with the terms of the Registration Rights Agreement,
and such lapse or unavailability continues for a period of 20 consecutive Trading Days or for more than an aggregate of 60 Trading Days
in any 365-day period, other than due to acts of the Investor; (e) trading in the Common Stock on the Trading Market (or if the Common
Stock is then listed on an Eligible Market, trading in the Common Stock on such Eligible Market) shall have been suspended and such suspension
continues for a period of three (3) consecutive Trading Days; or (f) the Company is in material breach or default of this Agreement,
and, if such breach or default is capable of being cured, such breach or default is not cured within 10 Trading Days after notice of
such breach or default is delivered to the Company pursuant to Section 10.4. Unless notification thereof is required elsewhere in this
Agreement (in which case such notification shall be provided in accordance with such other provision), the Company shall promptly (but
in no event later than 24 hours) notify the Investor (and, if required under applicable law, including, without limitation, Regulation
FD promulgated by the Commission, or under the applicable rules and regulations of the Trading Market, the Company shall publicly disclose
such information in accordance with Regulation FD and the applicable rules and regulations of the Trading Market) upon becoming aware
of any of the events set forth in the immediately preceding sentence.

 

    	37

    	 

    

 

Section
8.3. Effect of Termination. In the event of termination by the Company or the Investor (other than by mutual termination)
pursuant to Section 8.2, written notice thereof shall forthwith be given to the other party as provided in Section 10.4 and the transactions
contemplated by this Agreement shall be terminated without further action by either party. If this Agreement is terminated as provided
in Section 8.1 or Section 8.2, this Agreement shall become void and of no further force and effect, except that (i) the provisions of
Article V (Representations, Warranties and Covenants of the Company), Article IX (Indemnification), Article X (Miscellaneous) and this
Article VIII (Termination) shall remain in full force and effect indefinitely notwithstanding such termination, and, (ii) so long as
the Investor owns any Shares, the covenants and agreements of the Company contained in Article VI (Additional Covenants) shall remain
in full force and notwithstanding such termination for a period of six (6) months following such termination. Notwithstanding anything
in this Agreement to the contrary, no termination of this Agreement by any party shall (i) become effective prior to the first Trading
Day immediately following the settlement date related to any pending VWAP Purchase Notice that has not been fully settled in accordance
with the terms and conditions of this Agreement (it being hereby acknowledged and agreed that no termination of this Agreement shall
limit, alter, modify, change or otherwise affect any of the Company’s or the Investor’s rights or obligations under the Transaction
Documents with respect to any pending VWAP Purchase, and that the parties shall fully perform their respective obligations with respect
to any such pending VWAP Purchase under the Transaction Documents, provided all of the conditions to the settlement thereof set
forth in Article VII are timely satisfied), (ii) limit, alter, modify, change or otherwise affect the Company’s or the Investor’s
rights or obligations under the Registration Rights Agreement, all of which shall survive any such termination, or (iii) affect the Investor
Expenses Reimbursement payable to the Investor, all of which fees and expenses shall be non-refundable when paid on the Closing Date
pursuant to Section 10.1(i), regardless of whether any VWAP Purchases are made or settled hereunder or any subsequent termination of
this Agreement Nothing in this Section 8.3 shall be deemed to release the Company or the Investor from any liability for any breach or
default under this Agreement or any of the other Transaction Documents to which it is a party, or to impair the rights of the Company
and the Investor to compel specific performance by the other party of its obligations under the Transaction Documents to which it is
a party.

 

Article
IX

INDEMNIFICATION

 

Section
9.1. Indemnification of Investor. In consideration of the Investor’s execution and delivery of this Agreement and acquiring
the Shares hereunder and in addition to all of the Company’s other obligations under the Transaction Documents to which it is a
party, subject to the provisions of this Section 9.1, the Company shall indemnify and hold harmless the Investor, each of its directors,
officers, shareholders, members, partners, employees, representatives, agents and advisors (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title), each Person, if any, who
controls the Investor (within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange Act), and the respective
directors, officers, shareholders, members, partners, employees, representatives, agents and advisors (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title) of such controlling Persons
(each, an “Investor Party”), from and against all losses, liabilities, obligations, claims, contingencies,
damages, costs and expenses (including all judgments, amounts paid in settlement, court costs, reasonable attorneys’ fees and costs
of defense and investigation) (collectively, “Damages”) that any Investor Party may suffer or incur as a result
of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents to which it is a party or (b) any action, suit, claim or proceeding (including for these purposes
a derivative action brought on behalf of the Company) instituted against such Investor Party arising out of or resulting from the execution,
delivery, performance or enforcement of the Transaction Documents, other than claims for indemnification within the scope of Section
6 of the Registration Rights Agreement; provided, however, that (x) the foregoing indemnity shall not apply to any Damages
to the extent, but only to the extent, that such Damages resulted directly and primarily from a breach of any of the Investor’s
representations, warranties, covenants or agreements contained in this Agreement or the Registration Rights Agreement, and (y) the Company
shall not be liable under subsection (b) of this Section 9.1 to the extent, but only to the extent, that a court of competent jurisdiction
shall have determined by a final judgment (from which no further appeals are available) that such Damages resulted directly and primarily
from any acts or failures to act, undertaken or omitted to be taken by such Investor Party through its fraud, bad faith, gross negligence,
or willful or reckless misconduct.

 

    	38

    	 

    

 

The
Company shall reimburse any Investor Party promptly upon demand (with accompanying presentation of documentary evidence) for all legal
and other costs and expenses reasonably incurred by such Investor Party in connection with (i) any action, suit, claim or proceeding,
whether at law or in equity, to enforce compliance by the Company with any provision of the Transaction Documents or (ii) any other any
action, suit, claim or proceeding, whether at law or in equity, with respect to which it is entitled to indemnification under this Section
9.1; provided that the Investor shall promptly reimburse the Company for all such legal and other costs and expenses to the extent
a court of competent jurisdiction determines that any Investor Party was not entitled to such reimbursement.

 

An
Investor Party’s right to indemnification or other remedies based upon the representations, warranties, covenants and agreements
of the Company set forth in the Transaction Documents shall not in any way be affected by any investigation or knowledge of such Investor
Party. Such representations, warranties, covenants and agreements shall not be affected or deemed waived by reason of the fact that an
Investor Party knew or should have known that any representation or warranty might be inaccurate or that the Company failed to comply
with any agreement or covenant. Any investigation by such Investor Party shall be for its own protection only and shall not affect or
impair any right or remedy hereunder.

 

To
the extent that the foregoing undertakings by the Company set forth in this Section 9.1 may be unenforceable for any reason, the Company
shall make the maximum contribution to the payment and satisfaction of each of the Damages which is permissible under applicable law.

 

Section
9.2. Indemnification Procedures. Promptly after an Investor Party receives notice of a claim or the commencement of an action
for which the Investor Party intends to seek indemnification under Section 9.1, the Investor Party will notify the Company in writing
of the claim or commencement of the action, suit or proceeding; provided, however, that failure to notify the Company will
not relieve the Company from liability under Section 9.1, except to the extent it has been materially prejudiced by the failure to give
notice. The Company will be entitled to participate in the defense of any claim, action, suit or proceeding as to which indemnification
is being sought, and if the Company acknowledges in writing the obligation to indemnify the Investor Party against whom the claim or
action is brought, the Company may (but will not be required to) assume the defense against the claim, action, suit or proceeding with
counsel satisfactory to it. After the Company notifies the Investor Party that the Company wishes to assume the defense of a claim, action,
suit or proceeding, the Company will not be liable for any further legal or other expenses incurred by the Investor Party in connection
with the defense against the claim, action, suit or proceeding except that if, in the opinion of counsel to the Investor Party, it would
be inappropriate under the applicable rules of professional responsibility for the same counsel to represent both the Company and such
Investor Party. In such event, the Company will pay the reasonable fees and expenses of no more than one separate counsel for all such
Investor Parties promptly as such fees and expenses are incurred. Each Investor Party, as a condition to receiving indemnification as
provided in Section 9.1, will cooperate in all reasonable respects with the Company in the defense of any action or claim as to which
indemnification is sought. The Company will not be liable for any settlement of any action effected without its prior written consent,
which consent shall not be unreasonably withheld, delayed or conditioned. The Company will not, without the prior written consent of
the Investor Party, effect any settlement of a pending or threatened action with respect to which an Investor Party is, or is informed
that it may be, made a party and for which it would be entitled to indemnification, unless the settlement includes an unconditional release
of the Investor Party from all liability and claims which are the subject matter of the pending or threatened action.

 

The
remedies provided for in this Article IX are not exclusive and shall not limit any rights or remedies which may otherwise be available
to any Investor Party at law or in equity.

 

    	39

    	 

    

 

Article
X

MISCELLANEOUS

 

Section
10.1. Certain Fees and Expenses; Commencement Irrevocable Transfer Agent Instructions.

 

(i)
Certain Fees and Expenses. Each party shall bear its own fees and expenses related to the transactions contemplated by
this Agreement; provided, however, that the Company shall pay, on or prior to the Closing Date, by wire transfer of immediately
available funds to an account designated by the Investor on or prior to the date of this Agreement, an aggregate amount up to $35,000
as reimbursement for the Investor’s reasonable out-of-pocket expenses (including the Investor’s legal fees and expenses),
in connection with the transaction contemplated by the Transaction Documents (the “Investor Expense Reimbursement”).
For the avoidance of doubt, the Investor Expense Reimbursement shall be non-refundable when paid on the Closing Date, regardless of whether
any VWAP Purchases are made or settled hereunder or any subsequent termination of this Agreement. The Company shall pay all U.S. federal,
state and local stamp and other similar transfer and other taxes and duties levied in connection with issuance of the Shares pursuant
hereto.

 

(ii)
[Reserved].

 

(iii)
[Reserved].

 

(iv)
Irrevocable Transfer Agent Instructions; Notice of Effectiveness. On the Effective Date of the Initial Registration Statement
and prior to Commencement, the Company shall deliver or cause to be delivered to its transfer agent (and thereafter, shall deliver or
cause to be delivered to any subsequent transfer agent of the Company), (i) irrevocable instructions executed by the Company and acknowledged
in writing by the Company’s transfer agent (the “Commencement Irrevocable Transfer Agent Instructions”)
and (ii) the notice of effectiveness in the form attached as an exhibit to the Registration Rights Agreement (the “Notice
of Effectiveness”) relating to the Initial Registration Statement executed by the Company’s outside counsel, in each
case directing the Company’s transfer agent to issue to the Investor or its designee all of the Shares included in the Initial
Registration Statement as DWAC Shares in accordance with this Agreement and the Registration Rights Agreement. With respect to any post-effective
amendment to the Initial Registration Statement, any New Registration Statement or any post-effective amendment to any New Registration
Statement, in each case declared effective by the Commission after the Commencement Date, the Company shall deliver or cause to be delivered
to its transfer agent (and thereafter, shall deliver or cause to be delivered to any subsequent transfer agent of the Company) (i) irrevocable
instructions in the form substantially similar to the Commencement Irrevocable Transfer Agent Instructions executed by the Company and
acknowledged in writing by the Company’s transfer agent and (ii) the Notice of Effectiveness, in each case modified as necessary
to refer to such Registration Statement or post-effective amendment and the Registrable Securities included therein, to issue the Registrable
Securities included therein as DWAC Shares in accordance with the terms of this Agreement and the Registration Rights Agreement. For
the avoidance of doubt, all Shares to be issued from and after Commencement to or for the benefit of the Investor pursuant to this Agreement
shall be issued to the Investor or its designee only as DWAC Shares. The Company represents and warrants to the Investor that, while
this Agreement is effective, no instruction other than those referred to in this Section 10.1(iv) will be given by the Company to its
transfer agent, or any successor transfer agent of the Company, with respect to the Shares from and after Commencement, and the Shares
covered by the Initial Registration Statement or any post-effective amendment thereof, or any New Registration Statement or post-effective
amendment thereof, as applicable, shall otherwise be freely transferable on the books and records of the Company and no stop transfer
instructions shall be maintained against the transfer thereof. The Company agrees that if the Company fails to fully comply with the
provisions of this Section 10.1(iv) within three (3) Trading Days after the date on which the Investor has provided the deliverables
referred to above that the Investor is required to provide to the Company or its transfer agent, the Company shall, at the Investor’s
written instruction, purchase from the Investor all shares of Common Stock purchased or acquired by the Investor pursuant to this Agreement
that contain the restrictive legend referred to in Section 10.1(iii) hereof (or any similar restrictive legend) at the greater of (i)
the purchase price paid for such shares of Common Stock (as applicable) and (ii) the Closing Sale Price of the Common Stock on the date
of the Investor’s written instruction.

 

    	40

    	 

    

 

Section
10.2. Specific Enforcement, Consent to Jurisdiction, Waiver of Jury Trial.

 

(i)
The Company and the Investor acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that either
party shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement by the other
party and to enforce specifically the terms and provisions hereof (without the necessity of showing economic loss and without any bond
or other security being required), this being in addition to any other remedy to which either party may be entitled by law or equity.

 

(ii)
Each of the Company and the Investor (a) hereby irrevocably submits to the jurisdiction of the U.S. District Court and other courts of
the United States sitting in the State of New York for the purposes of any suit, action or proceeding arising out of or relating to this
Agreement, and (b) hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of such court, that the suit, action or proceeding is brought in an inconvenient forum or that the venue
of the suit, action or proceeding is improper. Each of the Company and the Investor consents to process being served in any such suit,
action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing in this Section 10.2 shall affect
or limit any right to serve process in any other manner permitted by law.

 

(iii)
EACH OF THE COMPANY AND THE INVESTOR HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL
BY JURY IN RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY OR DISPUTES RELATING HERETO. EACH OF THE COMPANY AND THE INVESTOR (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR
ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK
TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN TO ENTER INTO THIS AGREEMENT BY,
AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.2.

 

Section
10.3. Entire Agreement. The Transaction Documents set forth the entire agreement and understanding of the parties with respect
to the subject matter hereof and supersedes all prior and contemporaneous agreements, negotiations and understandings between the parties,
both oral and written, with respect to such matters. There are no promises, undertakings, representations or warranties by either party
relative to subject matter hereof not expressly set forth in the Transaction Documents. The Disclosure Schedule and all exhibits to this
Agreement are hereby incorporated by reference in, and made a part of, this Agreement as if set forth in full herein.

 

Section
10.4. Notices. Any notice, demand, request, waiver or other communication required or permitted to be given hereunder shall
be in writing and shall be effective (a) upon hand delivery or electronic mail delivery at the address or number designated below (if
delivered on a business day during normal business hours where such notice is to be received), or the first business day following such
delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second
business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt
of such mailing, whichever shall first occur. The address for such communications shall be:

 

If
to the Company:

 

Gaucho
Group Holdings, Inc.

112
NE 41St Street, Suite 106

Miami,
FL 33137

Telephone
Number: 212-739-7650

Email:
smathis@gauchogroup.com

Attention:
Scott Mathis, President & CEO

 

    	41

    	 

    

 

With
a copy (which shall not constitute notice) to:

 

Burns,
Figa & Will, P.C.

6400
S. Fiddler’s Green Circle, Suite 1000

Greenwood
Village, Colorado 80111

Telephone
Number: 303-796-2626

Email:
vbantz@bfwlaw.com

Attention:
Victoria Bantz, Esq.

 

If
to the Investor:

 

Tumim
Stone Capital LLC

140
Broadway, 38th Floor

New
York, NY 10005

Telephone
Number: (646) 845-0040

Email:
mjtarlow@3ifund.com

Attention:
Maier Joshua Tarlow

 

With
a copy (which shall not constitute notice) to:

 

Dorsey
& Whitney LLP

51
West 52nd Street

New
York, NY 10019

Telephone
Number: (212) 415-9214

Email:
marsico.anthony@dorsey.com

Attention:
Anthony J. Marsico, Esq.

 

Either
party hereto may from time to time change its address for notices by giving at least five (5) days’ advance written notice of such
changed address to the other party hereto.

 

Section
10.5. Waivers. No provision of this Agreement may be waived by the parties from and after the date that is one (1) Trading
Day immediately preceding the filing of the Initial Registration Statement with the Commission. Subject to the immediately preceding
sentence, no provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement
of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercises thereof or of any
other right, power or privilege.

 

Section
10.6. Amendments. No provision of this Agreement may be amended by the parties from and after the date that is one (1) Trading
Day immediately preceding the filing of the Initial Registration Statement with the Commission. Subject to the immediately preceding
sentence, no provision of this Agreement may be amended other than by a written instrument signed by both parties hereto.

 

Section
10.7. Headings. The article, section and subsection headings in this Agreement are for convenience only and shall not constitute
a part of this Agreement for any other purpose and shall not be deemed to limit or affect any of the provisions hereof. Unless the context
clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms
thereof. The terms “including,” “includes,” “include” and words of like import shall be construed
broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof”
and words of like import refer to this entire Agreement instead of just the provision in which they are found.

 

    	42

    	 

    

 

Section
10.8. Construction. The parties agree that each of them and their respective counsel has reviewed and had an opportunity to
revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved
against the drafting party shall not be employed in the interpretation of the Transaction Documents. In addition, each and every reference
to share prices and number of shares of Common Stock in any Transaction Document shall, in all cases, be subject to adjustment for any
stock splits, stock combinations, stock dividends, recapitalizations, reorganizations and other similar transactions that occur on or
after the date of this Agreement. Any reference in this Agreement to “Dollars” or “$” shall mean the lawful currency
of the United States of America. Any references to “Section” or “Article” in this Agreement shall, unless otherwise
expressly stated herein, refer to the applicable Section or Article of this Agreement.

 

Section
10.9. Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
successors. Neither the Company nor the Investor may assign this Agreement or any of their respective rights or obligations hereunder
to any Person.

 

Section
10.10. No Third Party Beneficiaries. Except as expressly provided in the immediately preceding sentence and in Article IX,
this Agreement is intended only for the benefit of the parties hereto and their respective successors, and is not for the benefit of,
nor may any provision hereof be enforced by, any other Person.

 

Section
10.11. Governing Law. This Agreement shall be governed by and construed in accordance with the internal procedural and substantive
laws of the State of New York, without giving effect to the choice of law provisions of such state that would cause the application of
the laws of any other jurisdiction.

 

Section
10.12. Survival. The representations, warranties, covenants and agreements of the Company and the Investor contained in this
Agreement shall survive the execution and delivery hereof until the termination of this Agreement; provided, however, that
(i) the provisions of Article V (Representations, Warranties and Covenants of the Company), Article VIII (Termination), Article IX (Indemnification)
and this Article X (Miscellaneous) shall remain in full force and effect indefinitely notwithstanding such termination, and, (ii) so
long as the Investor owns any Shares, the covenants and agreements of the Company and the Investor contained in Article VI (Additional
Covenants), shall remain in full force and effect notwithstanding such termination for a period of six months following such termination.

 

Section
10.13. Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party;
provided that a facsimile signature or signature delivered by e-mail in a “.pdf” format data file, including any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered
due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.

 

    	43

    	 

    

 

Section
10.14. Publicity. The Company shall afford the Investor and its counsel with a reasonable opportunity to review and comment
upon, shall consult with the Investor and its counsel on the form and substance of, and shall give due consideration to all such comments
from the Investor or its counsel on, any press release, Commission filing or any other public disclosure made by or on behalf of the
Company relating to the Investor, its purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated
thereby, prior to the issuance, filing or public disclosure thereof. For the avoidance of doubt, the Company shall not be required to
submit for review any such disclosure (i) contained in periodic reports filed with the Commission under the Exchange Act if it shall
have previously provided the same disclosure to the Investor or its counsel for review in connection with a previous filing or (ii) any
Prospectus Supplement if it contains disclosure that does not reference the Investor, its purchases hereunder or any aspect of the Transaction
Documents or the transactions contemplated thereby. The Company agrees and acknowledges that its failure to comply with this provision
in all material respects constitutes a Material Adverse Effect for purposes of Section 7.2(xi).

 

Section
10.15. Severability. The provisions of this Agreement are severable and, in the event that any court of competent jurisdiction
shall determine that any one or more of the provisions or part of the provisions contained in this Agreement shall, for any reason, be
held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other
provision or part of a provision of this Agreement, and this Agreement shall be reformed and construed as if such invalid or illegal
or unenforceable provision, or part of such provision, had never been contained herein, so that such provisions would be valid, legal
and enforceable to the maximum extent possible.

 

Section
10.16. Further Assurances. From and after the Closing Date, upon the request of the Investor or the Company, each of the Company
and the Investor shall execute and deliver such instrument, documents and other writings as may be reasonably necessary or desirable
to confirm and carry out and to effectuate fully the intent and purposes of this Agreement.

 

[Signature
Pages Follow]

 

    	44

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officer as of the
date first above written.

 

	 	GAUCHO
    GROUP HOLDINGS, INC.:
	 	 	 
	 	By:	/s/Scott
    L. Mathis
	 	Name:	Scott
    L. Mathis
	 	Title:
    	President
    & CEO
	 	 	 
	 	TUMIM
    STONE CAPITAL LLC:
	 	 	 
	 	By:
    	/s/Maier
    J. Tarlow
	 	Name:
    	Maier
    J. Tarlow
	 	Title:	Manager
    On Behalf Of The GP

 

    	 

    	 

    

 

ANNEX
I TO THE

COMMON STOCK PURCHASE AGREEMENT

DEFINITIONS

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control
with a Person, as such terms are used in and construed under Rule 144. With respect to the Investor, without limitation, any Person owning,
owned by, or under common ownership with the Investor, and any investment fund or managed account that is managed on a discretionary
basis by the same investment manager as the Investor will be deemed to be an Affiliate.

 

“Aggregate
Limit” shall have the meaning assigned to such term in Section 2.1.

 

“Agreement”
shall have the meaning assigned to such term in the preamble of this Agreement.

 

“Average
Price” means a price per Share (rounded to the nearest tenth of a cent) equal to the quotient obtained by dividing (i)
the aggregate gross purchase price paid by the Investor for all Shares purchased pursuant to this Agreement, by (ii) the aggregate number
of Shares issued pursuant to this Agreement.

 

“Bankruptcy
Law” means Title 11, U.S. Code, or any similar U.S. federal or state law for the relief of debtors.

 

“Beneficial
Ownership Limitation” shall have the meaning assigned to such term in Section 3.5.

 

“BHCA”
shall have the meaning assigned to such term in Section 5.39.

 

“Bloomberg”
means Bloomberg, L.P.

 

“Bring
Down Opinion” shall have the meaning assigned to such term in Section 6.15.

 

“Broker-Dealer”
shall have the meaning assigned to such term in Section 6.13.

 

“Bylaws”
shall have the meaning assigned to such term in Section 5.3.

 

“Charter”
shall have the meaning assigned to such term in Section 5.3.

 

“Closing”
shall have the meaning assigned to such term in Section 2.2.

 

“Closing
Date” means the date of this Agreement.

 

“Closing
Sale Price” means, for the Common Stock as of any date, the last closing trade price for the Common Stock on the Trading
Market, as reported by Bloomberg, or, if the Trading Market begins to operate on an extended hours basis and does not designate the closing
trade price for the Common Stock, then the last trade price for the Common Stock prior to 4:00 p.m., New York City time, as reported
by Bloomberg, or, if the foregoing do not apply, the last trade price for the Common Stock in the over-the-counter market on the electronic
bulletin board for the Common Stock as reported by Bloomberg, or, if no last trade price is reported for the Common Stock by Bloomberg,
the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported by OTC Markets Group
Inc. All such determinations shall be appropriately adjusted for any stock splits, stock dividends, stock combinations, recapitalizations
or other similar transactions during such period.

 

    	I-1

    	 

    

 

“Code”
shall have the meaning assigned to such term in Section 5.24 hereof.

 

“Commencement”
shall have the meaning assigned to such term in Section 3.2.

 

“Commencement
Date” shall have the meaning assigned to such term in Section 3.2.

 

“Commencement
Irrevocable Transfer Agent Instructions” shall have the meaning assigned to such term in Section 10.1(iii).

 

“Commission”
means the U.S. Securities and Exchange Commission or any successor entity.

 

“Commission
Documents” shall mean (1) all reports, schedules, registrations, forms, statements, information and other documents filed
with or furnished to the Commission by the Company pursuant to the reporting requirements of the Exchange Act, including all material
filed with or furnished to the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, since December 31, 2021,
including, without limitation, the Amended Annual Report on Form 10-K filed by the Company for its fiscal year ended December 31, 2021
(the “2021 Form 10-K”), and which hereafter shall be filed with or furnished to the Commission by the Company,
including, without limitation, the Current Report, (2) each Registration Statement, as the same may be amended from time to time, the
Prospectus contained therein and each Prospectus Supplement thereto and (3) all information contained in such filings and all documents
and disclosures that have been and heretofore shall be incorporated by reference therein.

 

“Common
Stock” shall have the meaning assigned to such term in the recitals of this Agreement.

 

“Common
Stock Equivalents” means any securities of the Company or its Subsidiaries which entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that
is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

“Company”
shall have the meaning assigned to such term in the preamble of this Agreement.

 

“Compliance
Certificate” shall have the meaning assigned to such term in Section 7.2(ii).

 

“Current
Report” shall have the meaning assigned to such term in Section 2.3.

 

“Cover
Price” shall have the meaning assigned to such term in Section 3.3.

 

    	I-2

    	 

    

 

“Custodian”
shall mean any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

 

“Damages”
shall have the meaning assigned to such term in Section 9.1.

 

“Disclosure
Schedule” shall have the meaning assigned to such term in the preamble to Article V.

 

“Disqualification
Event” shall have the meaning assigned to such term in Section 5.41.

 

“DTC”
means The Depository Trust Company, a subsidiary of The Depository Trust & Clearing Corporation, or any successor thereto.

 

“DWAC”
shall have the meaning assigned to such term in Section 5.33.

 

“DWAC
Shares” means shares of Common Stock issued pursuant to this Agreement that are (i) issued in electronic form, (ii) freely
tradable and transferable and without restriction on resale and without stop transfer instructions maintained against the transfer thereof
and (iii) timely credited by the Company to the Investor’s or its designated Broker-Dealer at which the account or accounts to
be credited with the Shares being purchased by Investor are maintained specified DWAC account with DTC under its Fast Automated Securities
Transfer (FAST) Program, or any similar program hereafter adopted by DTC performing substantially the same function.

 

“EDGAR”
means the Commission’s Electronic Data Gathering, Analysis and Retrieval System.

 

“Effective
Date” means, with respect to the Initial Registration Statement filed pursuant to Section 2(a) of the Registration Rights
Agreement (or any post-effective amendment thereto) or any New Registration Statement filed pursuant to Section 2(c) of the Registration
Rights Agreement (or any post-effective amendment thereto), as applicable, the date on which the Initial Registration Statement (or any
post-effective amendment thereto) or any New Registration Statement (or any post-effective amendment thereto) is declared effective by
the Commission.

 

“Effectiveness
Deadline” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“Eligible
Market” means the New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market, the NYSE American,
the NYSE Arca, or the OTCQX Best Market or OTCQB Venture Market operated by OTC Markets Group Inc. (or any nationally recognized successor
to any of the foregoing).

 

“Environmental
Laws” shall have the meaning assigned to such term in Section 5.18 hereof.

 

“ERISA”
shall have the meaning assigned to such term in Section 5.24 hereof.

 

“Evaluation
Date” shall have the meaning assigned to such term in Section 5.6(iii).

 

    	I-3

    	 

    

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.

 

“Exchange
Cap” shall have the meaning assigned to such term in Section 3.4(a)(i) hereof.

 

“Exempt
Issuance” means the issuance of (a) Common Stock, options or other equity incentive awards to employees, officers, directors
or vendors of the Company pursuant to any equity incentive plan duly adopted for such purpose, by the Company’s Board of Directors
or a majority of the members of a committee of the Board of Directors established for such purpose, (b) (1) any Shares issued to the
Investor pursuant to this Agreement, (2) any securities issued upon the exercise or exchange of or conversion of any shares of Common
Stock or Common Stock Equivalents held by the Investor at any time, or (3) any securities issued upon the exercise or exchange of or
conversion of any Common Stock Equivalents issued and outstanding on the date of this Agreement, provided that such securities referred
to in this clause (3) have not been amended since the date of this Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities, or (c) securities issued pursuant to acquisitions, divestitures,
licenses, partnerships, collaborations or strategic transactions approved by the Company’s Board of Directors or a majority of
the members of a committee of directors established for such purpose, which acquisitions, divestitures, licenses, partnerships, collaborations
or strategic transactions can have a Variable Rate Transaction component, provided that any such issuance shall only be to a Person (or
to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an asset in a business synergistic
with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall
not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose
primary business is investing in securities.

 

“FCPA”
shall have the meaning assigned to such term in Section 5.35.

 

“Federal
Reserve” shall have the meaning assigned to such term in Section 5.39.

 

“Filing
Deadline” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“FINRA”
means the Financial Industry Regulatory Authority.

 

“Fundamental
Transaction” means that (i) the Company shall, directly or indirectly, in one or more related transactions, (1) consolidate
or merge with or into (whether or not the Company is the surviving corporation) another Person, with the result that the holders of the
Company’s capital stock immediately prior to such consolidation or merger together beneficially own less than 50% of the outstanding
voting power of the surviving or resulting corporation, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of
all or substantially all of the properties or assets of the Company to another Person, or (3) take action to facilitate a purchase, tender
or exchange offer by another Person that is accepted by the holders of more than 50% of the outstanding shares of Common Stock (excluding
any shares of Common Stock held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party
to, such purchase, tender or exchange offer), or (4) consummate a stock or share purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or
other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase
agreement or other business combination), or (5) reorganize, recapitalize or reclassify its Common Stock, or (ii) any “person”
or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall become the
“beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of 50% of the aggregate ordinary
voting power represented by issued and outstanding Common Stock.

 

    	I-4

    	 

    

 

“GAAP”
shall have the meaning assigned to such term in Section 5.6(b).

 

“Hazardous
Materials” shall have the meaning assigned to such term in Section 5.18.

 

“Indebtedness”
shall have the meaning assigned to such term in Section 5.11.

 

“Initial
Registration Statement” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“Intellectual
Property Rights” shall have the meaning assigned to such term in Section 5.17(b).

 

“Investment
Period” means the period commencing on the Effective Date of the Initial Registration Statement and expiring on the date
this Agreement is terminated pursuant to Article VIII.

 

“Investor”
shall have the meaning assigned to such term in the preamble of this Agreement.

 

“Investor
Expense Reimbursement” shall have the meaning assigned to such term in Section 10.1(i) hereof.

 

“Investor
Party” shall have the meaning assigned to such term in Section 9.1.

 

“Issuer
Covered Person” shall have the meaning assigned to such term in Section 5.41.

 

“IT
Systems” shall have the meaning assigned to such term in Section 5.40.

 

“Knowledge”
means the actual knowledge of the Company’s Chief Executive Officer and Chief Financial Officer, after reasonable inquiry of all
officers, directors and employees of the Company and its Subsidiaries under their direct supervision who would reasonably be expected
to have knowledge or information with respect to the matter in question.

 

    	I-5

    	 

    

 

“Material
Adverse Effect” means (i) any condition, occurrence, state of facts or event having, or insofar as reasonably can be foreseen
would likely have, any material adverse effect on the legality, validity or enforceability of the Transaction Documents or the transactions
contemplated thereby, (ii) any condition, occurrence, state of facts or event having, or insofar as reasonably can be foreseen would
likely have, any effect on the business, operations, properties or financial condition of the Company that is material and adverse to
the Company and its Subsidiaries, taken as a whole, and/or (iii) any condition, occurrence, state of facts or event that would, or insofar
as reasonably can be foreseen would likely, prohibit or otherwise materially interfere with or delay the ability of the Company to perform
any of its obligations under any of the Transaction Documents to which it is a party; provided, however, that no facts,
circumstances, changes or effects exclusively and directly resulting from, relating to or arising out of the following, individually
or in the aggregate, shall be taken into account in determining whether a Material Adverse Effect has occurred or insofar as reasonably
can be foreseen would likely occur: (a) changes in conditions in the U.S. or global capital, credit or financial markets generally, including
changes in the availability of capital or currency exchange rates, provided such changes shall not have affected the Company in a materially
disproportionate manner as compared to other similarly situated companies; (b) changes generally affecting the industries in which the
Company and its Subsidiaries operate, provided such changes shall not have affected the Company and its Subsidiaries, taken as a whole,
in a materially disproportionate manner as compared to other similarly situated companies; (c) any effect of the announcement of, or
the consummation of the transactions contemplated by, this Agreement and the other Transaction Documents on the Company’s relationships,
contractual or otherwise, with customers, suppliers, vendors, bank lenders, strategic venture partners or employees; (d) changes arising
in connection with earthquakes, hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening
of any such hostilities, acts of war, sabotage or terrorism or military actions existing as of the date hereof; (e) any action taken
by the Investor, its affiliates or its or their successors and assigns with respect to the transactions contemplated by this Agreement;
and (f) the effect of any changes in applicable laws or accounting rules, provided such changes shall not have affected the Company in
a materially disproportionate manner as compared to other similarly situated companies.

 

“Material
Agreements” shall have the meaning assigned to such term in Section 5.19.

 

“Minimum
Price” means $1.56, representing the Nasdaq official closing price of the Common Stock on the Trading Market (as reflected
on Nasdaq.com) on the Closing Date (subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse
stock split or other similar transaction that occurs on or after the Closing Date).

 

“Money
Laundering Laws” shall have the meaning assigned to such term in Section 5.36.

 

“New
Registration Statement” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“Notice
of Effectiveness” shall have the meaning assigned to such term in Section 10.1(iii).

 

“PEA
Period” means the period commencing at 9:30 a.m., New York City time, on the fifth (5th) Trading Day immediately
prior to the filing of any post-effective amendment to the Initial Registration Statement or any New Registration Statement, and ending
at 9:30 a.m., New York City time, on the Trading Day immediately following, the Effective Date of such post-effective amendment.

 

    	I-6

    	 

    

 

“Person”
means any person or entity, whether a natural person, trustee, corporation, partnership, limited partnership, limited liability company,
trust, unincorporated organization, business association, firm, joint venture, governmental agency or authority.

 

“Personal
Data” shall have the meaning assigned to such term in Section 5.40.

 

“Plan”
shall have the meaning assigned to such term in Section 5.24.

 

“Prospectus”
means the prospectus in the form included in a Registration Statement, as supplemented from time to time by any Prospectus Supplement,
including the documents incorporated by reference therein.

 

“Prospectus
Supplement” means any prospectus supplement to the Prospectus filed with the Commission from time to time pursuant to Rule
424(b) under the Securities Act, including the documents incorporated by reference therein.

 

“Registrable
Securities” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“Registration
Rights Agreement” shall have the meaning assigned to such term in the recitals hereof.

 

“Registration
Statement” shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“Regulation
D” shall have the meaning assigned to such term in the recitals of this Agreement.

 

“Restricted
Period” shall have the meaning assigned to such term in Section 6.9(i).

 

“Restricted
Person” shall have the meaning assigned to such term in Section 6.9(i).

 

“Restricted
Persons” shall have the meaning assigned to such term in Section 6.9(i).

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect.

 

“Sale
Price” means any trade price for a share of Common Stock on the Trading Market, or if the Common Stock is then traded on
an Eligible Market, on such Eligible Market, as reported by Bloomberg.

 

“Sarbanes-Oxley
Act” shall have the meaning assigned to such term in Section 5.6(e).

 

“Section
4(a)(2)” shall have the meaning assigned to such term in the recitals of this Agreement.

 

“Securities
Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.

 

    	I-7

    	 

    

 

“Shares”
shall mean the shares of Common Stock that are and/or may be purchased by the Investor under this Agreement pursuant to one or more VWAP
Purchase Notices.

 

“Short
Sales” shall mean “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange
Act.

 

“Subsidiary”
shall mean any corporation or other entity of which at least a majority of the securities or other ownership interest having ordinary
voting power for the election of directors or other persons performing similar functions are at the time owned directly or indirectly
by the Company and/or any of its other Subsidiaries.

 

“Total
Commitment” shall have the meaning assigned to such term in Section 2.1.

 

“Trading
Day” shall mean a full trading day (beginning at 9:30:01 a.m., New York City time, and ending at 4:00 p.m., New York City
time) on the Trading Market or, if the Common Stock is then listed on an Eligible Market, on such Eligible Market.

 

“Trading
Market” means The Nasdaq Capital Market (or any nationally recognized successor thereto).

 

“Transaction
Documents” means, collectively, this Agreement (as qualified by the Disclosure Schedule) and the exhibits hereto, the Registration
Rights Agreement and each of the other agreements, documents, certificates and instruments entered into or furnished by the parties hereto
in connection with the transactions contemplated hereby and thereby.

 

“Variable
Rate Transaction” means a transaction in which the Company (i) issues or sells any equity or debt securities that are convertible
into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock or Common Stock Equivalents
either (A) at a conversion price, exercise price, exchange rate or other price that is based upon and/or varies with the trading prices
of or quotations for the Common Stock at any time after the initial issuance of such equity or debt securities, or (B) with a conversion,
exercise or exchange price that is subject to being reset at some future date after the initial issuance of such equity or debt security
or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market
for the Common Stock (including, without limitation, any “full ratchet” or “weighted average” anti-dilution provisions,
but not including any standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend, stock split or other
similar transaction), (ii) issues or sells any equity or debt securities, including without limitation, Common Stock or Common Stock
Equivalents, either (A) at a price that is subject to being reset at some future date after the initial issuance of such debt or equity
security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the
market for the Common Stock (other than standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend,
stock split or other similar transaction), or (B) that are subject to or contain any put, call, redemption, buy-back, price-reset or
other similar provision or mechanism (including, without limitation, a “Black-Scholes” put or call right, other than in connection
with a “fundamental transaction”) that provides for the issuance of additional equity securities of the Company or the payment
of cash by the Company, or (iii) enters into any agreement, including, but not limited to, an “equity line of credit” or
“at the market offering” or other continuous offering or similar offering of Common Stock or Common Stock Equivalents, whereby
the Company may sell Common Stock or Common Stock Equivalents at a future determined price.

 

    	I-8

    	 

    

 

“VWAP”
means, for the Common Stock as of any Trading Day, the dollar volume-weighted average price for the Common Stock on the Trading Market
(or, if the Common Stock is then listed on an Eligible Market, on such Eligible Market) during the period beginning at 9:30:01 a.m.,
New York City time, or such other time publicly announced by the Trading Market (or by such Eligible Market, as applicable) as the official
open (or commencement) of trading on the Trading Market (or on such Eligible Market, as applicable) on such Trading Day, and ending at
4:00 p.m., New York City time, or such other time publicly announced by the Trading Market (or by such Eligible Market, as applicable)
as the official close of trading on the Trading Market (or on such Eligible Market, as applicable) on such Trading Day, as reported by
Bloomberg through its “AQR” function or, if no dollar volume-weighted average price is reported for the Common Stock by Bloomberg
through its “AQR” function for such hours, the average of the highest closing bid price and the lowest closing ask price
of any of the market makers for such security on such Trading Day as reported by OTC Markets Group Inc. All such determinations shall
be appropriately adjusted for any stock dividend, stock split, stock combination, recapitalization or other similar transaction during
such period.

 

“VWAP
Purchase” shall have the meaning assigned to such term in Section 3.2.

 

“VWAP
Purchase Confirmation” shall have the meaning assigned to such term in Section 3.2.

 

“VWAP
Purchase Commencement Time” means, with respect to a VWAP Purchase made pursuant to Section 3.2, 9:30:01 a.m., New York
City time, on the Trading Day immediately following the applicable VWAP Purchase Exercise Date, or such other time publicly announced
by the Trading Market as the official open (or commencement) of trading on the Trading Market on such Trading Day.

 

“VWAP
Purchase Date” shall have the meaning assigned to such term in Section 3.2.

 

“VWAP
Purchase Exercise Date” means, with respect to a VWAP Purchase made pursuant to Section 3.2, the Trading Day on which the
Investor receives, after 4:00 p.m., New York City time, but prior to 5:00 p.m., New York City time, on such Trading Day, a valid VWAP
Purchase Notice for such VWAP Purchase in accordance with this Agreement.

 

“VWAP
Purchase Maximum Amount” means, with respect to a VWAP Purchase made pursuant to Section 3.2, a number of shares of Common
Stock equal to the lesser of (i) $250,000 divided by the applicable VWAP on the VWAP Purchase Exercise Date and (ii) 35% of the average
volume over the three (3) consecutive Trading-Day Period immediately prior to the applicable VWAP Purchase Exercise Date.

 

“VWAP
Purchase Notice” means, with respect to a VWAP Purchase made pursuant to Section 3.2, an irrevocable written notice delivered
by the Company to the Investor on a VWAP Purchase Exercise Date directing the Investor to purchase a VWAP Purchase Share Amount (such
specified VWAP Purchase Share Amount subject to adjustment as set forth in Section 3.2 as necessary to give effect to the VWAP Purchase
Maximum Amount), at the applicable VWAP Purchase Price therefor in accordance with this Agreement.

 

“VWAP
Purchase Price” means, with respect to a VWAP Purchase made pursuant to Section 3.2, the purchase price per Share to be
purchased by the Investor in such VWAP Purchase equal to ninety-five percent (95%) of the lowest daily VWAP during the applicable VWAP
Purchase Valuation Period for such VWAP Purchase (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend,
stock split, reverse stock split or other similar transaction).

 

“VWAP
Purchase Share Amount” means, with respect to a VWAP Purchase made pursuant to Section 3.2, the number of Shares to be
purchased by the Investor in such VWAP Purchase as specified by the Company in the applicable VWAP Purchase Notice, which number of Shares
shall not exceed the applicable VWAP Purchase Maximum Amount.

 

“VWAP
Purchase Termination Time” means, with respect to a VWAP Purchase made pursuant to Section 3.2, 4:00:00 p.m., New York
City time, on the third (3rd) consecutive Trading Day immediately following the applicable VWAP Purchase Exercise Date, or
such other time publicly announced by the Trading Market as the official close of trading on the Trading Market on such third (3rd)
consecutive Trading Day immediately following the applicable VWAP Purchase Exercise Date.

 

“VWAP
Purchase Valuation Period” means, with respect to a VWAP Purchase made pursuant to Section 3.2, the three (3) consecutive
Trading-Day Period immediately following the applicable VWAP Purchase Exercise Date, beginning at the VWAP Purchase Commencement Time
for such VWAP Purchase and ending at the applicable VWAP Purchase Termination Time for such VWAP Purchase.

 

    	I-9

    	 

    

 

EXHIBIT
A TO THE

COMMON STOCK PURCHASE AGREEMENT

 

[TO
BE FURNISHED SEPARATELY]

 

    	A-1

    	 

    

 

EXHIBIT
B TO THE

COMMON STOCK PURCHASE AGREEMENT

CERTiFICATE OF THE COMPANY

 

CLOSING
CERTIFICATE

 

[●],
2022

 

The
undersigned, the Chief Financial Officer, Treasurer and Secretary of Gaucho Group Holdings, Inc., a Delaware corporation (the “Company”),
delivers this certificate in connection with the Common Stock Purchase Agreement, dated as of November 8, 2022(the “Agreement”),
by and between the Company and Tumim Stone Capital LLC, a Delaware limited liability company (the “Investor”),
and hereby certifies on the date hereof that (capitalized terms used herein without definition have the meanings assigned to them in
the Agreement):

 

1.
Attached hereto as Exhibit A is a true, complete and correct copy of the Certificate of Incorporation of the Company, as amended
through the date hereof, as filed with the Secretary of State of the State of Delaware. The Certificate of Incorporation of the Company
has not been further amended or restated, and no document with respect to any amendment to the Certificate of Incorporation of the Company
has been filed in the office of the Secretary of State of the State of Delaware since the date shown on the face of the state certification
relating to the Company’s Certificate of Incorporation, which is in full force and effect on the date hereof, and no action has
been taken by the Company in contemplation of any such amendment or the dissolution, merger or consolidation of the Company.

 

2.
Attached hereto as Exhibit B is a true and complete copy of the Bylaws of the Company, as amended and restated through, and as
in full force and effect on, the date hereof, and no proposal for any amendment, repeal or other modification to the Bylaws of the Company
has been taken or is currently pending before the Board of Directors or stockholders of the Company.

 

3.
The Board of Directors of the Company has approved the transactions contemplated by the Transaction Documents; said approval has not
been amended, rescinded or modified and remains in full force and effect as of the date hereof. Attached hereto as Exhibit C are
true, correct and complete copies of the resolutions duly adopted by the Board of Directors of the Company via unanimous written consent
on [●], 2022.

 

4.
Each person who, as an officer of the Company, or as attorney-in-fact of an officer of the Company, signed the Transaction Documents
to which the Company is a party, was duly elected, qualified and acting as such officer or duly appointed and acting as such attorney-in-fact,
and the signature of each such person appearing on any such document is his genuine signature.

 

IN
WITNESS WHEREOF, I have signed my name as of the date first above written.

 

	 	
	 	Name:
	 	Title:

 

    	B-1

    	 

    

 

EXHIBIT
C TO THE

COMMON STOCK PURCHASE AGREEMENT

COMPLIANCE CERTIFICATE

 

The
undersigned, the Chief Financial Officer, Treasurer and Secretary of Gaucho Group Holdings, Inc., a Delaware corporation (the “Company”),
delivers this certificate in connection with the Common Stock Purchase Agreement, dated as of November 8, 2022 (the “Agreement”),
by and between the Company and Tumim Stone Capital LLC, a Delaware limited liability company (the “Investor”),
and hereby certifies on the date hereof that, to the best of his knowledge after reasonable investigation, on behalf of the Company (capitalized
terms used herein without definition have the meanings assigned to them in the Agreement):

 

1.
The undersigned is the duly appointed [●] of the Company.

 

2.
Except as set forth in the attached Disclosure Schedule, the representations and warranties of the Company set forth in Article V of
the Agreement (i) that are not qualified by “materiality” or “Material Adverse Effect” are true and correct in
all material respects as of [the Commencement Date] [the date hereof] with the same force and effect as if made on [the Commencement
Date] [the date hereof], except to the extent such representations and warranties are as of another date, in which case, such representations
and warranties are true and correct in all material respects as of such other date and (ii) that are qualified by “materiality”
or “Material Adverse Effect” are true and correct as of [the Commencement Date] [the date hereof] with the same force and
effect as if made on [the Commencement Date] [the date hereof], except to the extent such representations and warranties are as of another
date, in which case, such representations and warranties are true and correct as of such other date.

 

3.
The Company has performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by
the Agreement and the Registration Rights Agreement to be performed, satisfied or complied with by the Company [at or prior to Commencement][on
or prior to the date hereof].

 

4.
The Shares issuable in respect of each VWAP Purchase Notice effected pursuant to the Agreement shall be delivered to the Investor electronically
as DWAC Shares, and shall be freely tradable and transferable and without restriction on resale and without any stop transfer instructions
maintained against such Shares.

 

5.
As of [the Commencement Date][the date hereof], the Company does not possess any material non-public information.

 

6.
As of [the Commencement Date][the date hereof], the Company has reserved out of its authorized and unissued Common Stock, [●] shares
of Common Stock solely for the purpose of effecting VWAP Purchases under the Agreement.

 

7.
No stop order suspending the effectiveness of the Registration Statement or the use of the Prospectus under the Securities Act has been
issued and no proceedings for such purpose or pursuant to Section 8A of the Securities Act are pending before or, to the knowledge of
the Company, threatened by the Commission.

 

The
undersigned has executed this Certificate this [●] day of [●], 20[●].

 

	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	C-1

    	 

    

 

DISCLOSURE
SCHEDULE

RELATING TO THE COMMON STOCK

PURCHASE AGREEMENT, DATED AS OF November 8, 2022

BETWEEN GAUCHO GROUP HOLDINGS, INC. AND TUMIM STONE capital llc

 

This
disclosure schedule is made and given pursuant to Article V of the Common Stock Purchase Agreement, dated as of November 8, 2022 (the
“Agreement”), by and between Gaucho Group Holdings, Inc., a Delaware corporation (the “Company”),
and Tumim Stone Capital LLC, a Delaware limited liability company. Unless the context otherwise requires, all capitalized terms are used
herein as defined in the Agreement. The numbers below correspond to the section numbers of representations and warranties in the Agreement
most directly modified by the below exceptions.

 

Section
5.15: Fee of 8% of Total Commitment actually paid by Investor to Company payable to Kingswood Capital Markets.

 

Section
5.18 ERISA: The Company has a 401(k) plan for its employees.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]